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Collaboration between biologists and chemists has generated medicines of 
enormous benefit to society. The resulting contributions to the practice of medicine 
have reduced morbidity and mortality while increasing the quality of life. Medicinal 
chemists have advanced rational drug discovery to a degree unthinkable even twenty 
years ago, and yet have only begun to scratch the surface of possible opportunities. 
Some of the most remarkable discoveries in medicinal chemistry have been achieved in 
the area of peptide research1.
Peptides occur throughout nature in a range of roles, from extracellular 
messengers in plants and animals, to structural uses such as keratin in hair and nails. 
Peptides are the primary means of intercellular communication in many diverse 
m biological systems. Acting as neurotransmitters, neuromodulators, and hormones they 
influence a multitude of physiological processes by interacting with peptide 
receptors2. In addition, over the last twenty years their role in the appearance or 
maintenance of various diseases has been unequivocally proven3.
Historically, new lead compounds have been discovered either by serendipity or 
by mass screening o f libraries of natural and synthetic compounds through multiple 
bioassays. Using mass screening, lead compounds are obtained with low success rates 
(rarely greater than 1 in 80,000 screened compounds) and then painstakingly modified 
by chemical synthesis in the search for improved bioactivity and reduced toxicity.
This analogue-based approach to drug development requires large numbers of 
synthetic analogues in order to develop structure-activity profiles. Over the past 30 
years, through a better understanding of disease processes, mechanism-based drug 
design has evolved and produced compounds that interrupt biochemical pathways 
(usually by mimicking a transition state).
During the past decade, advances in molecular biology and protein chemistry 
have provided pure proteins in sufficient quantities to allow structural studies to be 
carried out. These developments, coupled with advances in X-ray crystallography, 
n.m.r. spectroscopy, and computing technology, have greatly accelerated the 
determination of 3D structures of proteins. Visualisation of these structures by 
sophisticated computer graphics has made receptor-based drug design feasible. 
Receptor-based drug design, unlike earlier methods of drug discovery, allows the 
examination of all interactions between the bioactive molecule and a drug target at 
atomic level; hence, it can facilitate the identification o f divergent classes of 
compounds with correspondingly divergent biological properties. This permits rational 
development of structurally distinct compounds with different pharmacological 
profiles.
In the last few years new methods have been established for the treatment and 
therapy of diseases, and hopes have also been raised for the therapy of other diseases 
in which peptides have been implicated. However, peptides lack the appropriate 
physical chemical properties and metabolic stability to be ideally suited to 
therapeutics3.
3These pharmacological problems include:
(1) Short serum half-life values and high susceptibility to hydrolysis by degradative 
enzymes present in the bloodstream, gut, and cells.
(2) Poor absorption and oral bioavailability.
(3) Rapid liver clearance and biliary excretion.
(4) Undesired effects caused by interaction with various receptors other than those 
required, due to flexible conformation of the peptide.
Despite these disadvantages the development of peptide-based therapeutic 
drugs is, at present, one of the most active areas of medicinal research. In order to 
solve the problems encountered in using peptides as therapeutic agents 
peptidomimetics have been synthesised.
Peptidomimetics
A peptidomimetic is a molecule with some or all of its peptide functionality 
replaced by some other organic functionality, but which retains properties analogous to 
the peptide, i.e. as the ligand of a receptor it can imitate the biological effect of the 
native peptide at the receptor level 2t3.
In order to improve the stability and bioavailability of inhibitors various 
synthetic modifications need to be made. Half-lives might be extended by attaching the 
compounds to carrier molecules, or by decreasing susceptibility to degradation by 
sterically protecting or removing amide bonds.
4Higher gastrointestinal absorption, better cellular membrane penetration, and 
lower hepatic clearance might be achieved by using low molecular mass (Mr < 600) 
inhibitors with more appropriate water-lipid solubilities. Smaller inhibitors might only 
occupy four, three or even two side chain positions in the active site, and will need to 
be tested for their ability to dissolve in and diffuse through lipid membranes.
From the pharmacological and medicinal viewpoint it is frequently desirable to 
not only imitate the effect of the peptide at the receptor level (an agonist) but also to 
block the receptor when required (an antagonist). Agents that can imitate or block the 
biological functions of bioactive peptides can be considered as aids for the 
investigation of peptide systems and also as possible new types of treatment and 
therapy for a series of diseases.
The successes in this area cannot be denied. The marked trend of the last few 
years is the design of effective , orally active nonpeptide ligands for peptide 
receptors3. Of significance in this regard is the feet that it is possible, in principle, to 
imitate or to block the function of a relatively large peptide at the receptor level with 
low molecular mass compounds. In addition to the therapeutic side, modified peptides 
offer new insights into the nature of peptide and protein chemistry.
In comparison with native peptides these mimetics should show higher 
metabolic stability, better bioavailability, and longer duration of action. Peptidomimetic 
research owes its impetus to this desire to discover nonpeptides that bind to peptide 
receptors, but which have better bioavailability, biostability, and possibly greater 
selectivity than native, endogenous peptide ligands.
AIMS OF THE PROJECT
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It was proposed that we should find an effective mimic for the cysteine- 
cysteine disulphide bond. This peptide functionality was targeted for a number of 
reasons: It would provide us with a method of altering cyclic peptide structure and 
conformation, enable us to potentially control the formation and disassembly of 
discrete disulphide links, and afford peptidomimetics with possible therapeutic - 
properties. To expand on the second point, disulphide bridges are formed 
systematically during protein folding and disulphide bond formation, breakage, and 
rearrangement are a useful tool for identifying intermediates in protein folding 
pathways. Thus, we want a disulphide surrogate that would potentially mimic the 
transition state that the disulphide bond goes through during the breaking / formation 
of the S-S bond.
There are many reports in the literature of modifications to cysteine designed to 
evoke conformational restrictions. An example of these is the replacement of the 
disulphide bridge (-CH2-S-S-CH2 -) by three natural diamino diacids: djenkolic acid 
(-CH2-S-CH2-S-CH2 -); lanthionine (-CH2-S-CH2 -) ; and cystathione 
(-CH2-S-CH2-CH2 -) 4. The resulting compounds were selective linear competitive 
inhibitors for trypanothione reductase versus trypanothione, its physiological substrate, 
and this is discussed in further detail in the chapter on biological targets. The three 
surrogates were chosen because the resulting compounds did not act as substrates and 
the distances between both peptidic chains was only slightly modified.
However, these substitutes, and those like them, do not mimic the 
orthogonality that a disulphide bond elicits on the cysteine p-carbons. A feature of the 
disulphide bridge is the angle of +90° or -90° subtended by the (p)-C-S bonds in each 
cysteine, (the barrier of rotation is approximately lOKcal). A suitable moiety of 
comparable configuration was therefore sought. It was recognised that the most 
suitable mimic for this geometry is the allene unit, which exhibits analogous 
orthogonality, although the distance between Qa) and Q a> is 4.0 A for the S-S hpnd 
but 0.5 A longer for the allene surrogate. It is not yet known if this will affect the use 
o f allene surrogates in therapeutic peptidomimetics, but it does mimic the transition 
state the S-S bonds go through on assembly / disassembly, (fig. 1).
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The central carbon atom of the cumulated 1,2-diene system is sp-hybridised with two 
sets of orthogonal p-orbitals available for overlap with the remaining p-orbitals o f the 
two terminal sp2 -carbon atoms of the diene, (fig. 2). For maximum overlap to occur 
between the p-orbitals, the resulting 7i-bonds must be orthogonal to each other.
7In the proposed cysteine-mimic, the allene unit can exist in two enantiomeric 
forms. Thus both ( R) and ( S) configurations are possible giving +90° and -90° 
dihedral angle variability. This is of particular value, since conformational restriction is 
imposed, because it enables further investigation of the effect of the torsion angle 
orientation on the overall conformation of the peptide.
Allenes have been used previously in medicinal chemistry, where it has been 
found that their introduction enhanced or modified biological activity 5, and during the 
last few years allenes have begun to play a crucial role in the development of 
peptidomimetics. For example, the introduction o f the allene function into steroids has 
proven highly successful and has led to the discovery of pharmacologically very active 
compounds. In fact, an allenic analogue of the contraceptive norethisterone was found 
to be 10-20 times more active than the parent compound 6 .
Since the biological targets set out below all require the allene unit to be part of 
a larger peptide sequence it is proposed that protected allenyl Zus-amino acids,
(fig. 3a), will be synthesised as single diastereomers. These will be transformed into the 
transition state surrogate, (fig. 3b), in which the allenyl unit has appropriate 
recognition amino acids AA1 - AA4. It may be appropriate that in the transition state 
surrogate, AA1 and AA3 should be part of a monocyclic peptide, as is required for the 
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Disulphide Bond Formation
With disulphide links playing such an important role in the project it is worth 
considering the formation of disulphide bonds.
Disulphide bond formation between cysteine residues (Cys) has been studied 
extensively in vitro1, but how it occurs naturally after biosynthesis is not known. The 
mechanism of disulphide bond formation in vivo is thought to involve thiol-disulphide 
exchange between the protein synthesised with free SH groups on its Cys residues and 
small-molecule disulphide compounds. The predominant thiol compound in most cells 
is glutathione, which exists in both the thiol (GSH) and the disulphide (GSSG) forms. 
Formation of one disulphide bond in a protein requires two sequential thiol-disulphide 
exchanges involving the mixed disulphide intermediate, (fig.4). The protein becomes 
oxidised and the glutathione is reduced. The initial steps in thiol-disulphide interchange 
are the deprotonation of the dithiol and an Sn2 reaction involving the dithiolate anion, 
the nucleophilic attack of a thiol on a disulphide has not been observed7’8.
BIOLOGICAL TARGETS
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There are three main biological targets of the project, and these will be 
discussed below:
1. Competitive / Suicide inhibitor of Glutathione / Trypanothione reductases.
2. As a hapten for the creation of antibodies with disulphide bond formation / 
isomerisation / cleavage activity.
3. As a redox stable linkage in C2 symmetric (HIV) protease inhibitors.
Biological Target No. 1:
Competitive /  Suicide inhibitors o f Glutathione /  Trypanothione reductases
Viewed globally, parasitic diseases such as malaria and Chagas’ cardiopathy 
M pose an increasing threat to human health and welfare.
Malaria
In the last 25 years malaria has regained its former position as the greatest 
threat to the health and economic prosperity of mankind. According to figures 
published by the World Health Organisation, 1500 million people live in areas where 
malaria is endemic, 300 million cases are recorded each year, and more than two 
million - mostly children under five years old - die from malaria; an unknown number 
are left crippled or chronically ill9. The development of a vaccine against malaria has 
so far not fulfilled expectations, although some synthetic peptide vaccines are still in 
field trials.
10
Malaria pathogens are most adaptable to chemical changes in their 
environment. Following the introduction of a new drug, it can be anticipated that 
Plasmodeum falciparum , the protozoa responsible for the disease, will develop 
resistance within a few years 9.
Chagas’ Heart Disease
In 1909 the Brazilian scientist Carlos Chagas discovered the parasite flagellate 
which causes American Trypanosomiasis, better known as Chagas’ disease10’11. Chagas 
named this new protozoa Trypanosoma cruzi, and along with the interrelated 
Leishmanias and Crithidias, is responsible for many of the severe infectious diseases 
of man and domestic animals in tropical countries, although Crithidias is only 
pathogenic for insects. Examples along with Chagas’ disease are, African sleeping 
sickness, oriental sore and the devastating cattle disease Nagana. According to the 
World Health Organisation Chagas’ disease affects approximately 24 million people 
from Southern California to Argentina and Chile, and is after malaria, the most 
prevalent vector-borne Latin American disease 9*n .
The available treatments for human tropical diseases caused by parasitic 
trypanosomes and leishmanias lag far behind the enormous advances in the 
chemotherapy of bacterial diseases. Current drug treatment is either lacking or 
unsatisfactory, and new drugs for clinical use are too expensive to develop through 
classical screening methods. Chagas’ disease is being fought at present mainly through 
the elimination of the carrier with insecticides and better housing 12.
11
Educational campaigns, especially among young people, are becoming a veiy 
useful way to combat the disease, but there is still an imperative need to find new 
molecules which are more specific and more effective against these organisms.
• Targets for Drug Design :
Factors such as the metabolic pathways and individual enzymes operative in 
parasites have been characterised and may be exploited for the design of new drugs. 
Based on the knowledge of the structure of these molecules, the modelling of enzyme 
inhibitors as potential chemotherapeutic agents against parasites has become possible. 
In biochemical terms a common feature o f Trypanosomes and malaria parasites is their 
need for a highly efficient thiol metabolism to protect them from reactive oxygen
derivative and other oxidants9. These reactive oxygen species, such as O2* , H2O’ ,
HO’, H2O2 , are cytotoxic because of their ability to modify nucleic acids, thiol
containing proteins and membrane lipids. There are numerous metabolic pathways for 
the detoxification of reactive oxygen species, and when these antioxidative systems are 
challenged the cell or tissue is regarded as being under oxidative stress. Without 
exception, all organisms contain high concentrations of at least one low-molecular 
weight thiol for maintenance of an intracellular reducing environment. This Achilles 
heel of parasites, their sensitivity to oxidative stress, is a promising point of attack for 
drug design.
As drug targets the two disulphide flavoenzymes glutathione reductase (GR), and 
trypanothione reductase (TR) were chosen.
G lutathione:
12
Glutathione plays and important role in protecting cells from oxidative 
damage9’10. Due to its free sulphydryl group, GSH may serve as both a nucleophile and 
a reducing agent, two functions that are facilitated by the action of GSH-dependent 
enzymes such as the glutathione transferases and glutathione peroxidase. Thus, 
hazardous electrophilic metabolites may be converted to GSH conjugates through 
nucleophilic addition or substitution reactions, whereas reactive oxygen species and 
organic hydroperoxides are reduced to stable products with the concomitant formation 
of oxidised glutathione (GSSG)13.
Glutathione peroxidase catalyses the GSH-dependent reduction of H2O2 , and 
is a major pathway of H2O2 metabolism in many cells, and one which also catalyses the 
reduction of other peroxides. Together with superoxide dismutase and catalase these 
~ enzymes are important for the protection of membrane lipids against oxidation by
reactive oxygen intermediates such as O2*, (V , and H2O2 , (figure 5).
2 O2 '" + 2H+ 5100 > 0 2 + H20 2
2 H20 2 CAT > 0 2 + 2H20
GP&S6
H2O2 + 2 G SH ------------> GSSG + 2H20
(Where GSSG is glutathione disulphide.)
Fig. 5
13
Limiting the quantity of GSH in cells should prevent parasites from overcoming 
the oxidative stress pathways of the immune system. Human Lymphoid cells depleted 
of GSH exhibit increased sensitivity to irradiation, while tumour cells depleted of GSH 
by treatment with buthionine sulphoxime, an inhibitor of GSH synthesis, exhibit 
increased sensitivity to cytolysis by reactive oxygen intermediates. Also, the treatment 
of mice infected with tiypanosomes with buthionine sulphoxime led to prolonged 
survival o f the animals14. Not only can we deplete levels of GSH by restricting its 
synthesis9’14’15 but we can also inhibit the reduction of glutathione disulphide (GSSG), 
which results in GSH formation. Reduction of GSSG to GSH is catalysed by 





Tiypanosomes and their relatives exhibit a large number of metabolic reactions 
not seen in other micro-organisms and higher organisms. In contrast to almost all other 
organisms whose intracellular redox equilibrium depends on the glutathione / 
glutathione reductase system, trypanosomatids have no glutathione reductase9’15'17.
14
Their most important thiols are compounds in which the sulphur-containing 
tripeptide glutathione is conjugated to the tripeptide spermidine by an amide bond to 
form trypanothione, (scheme 2). The reduced disulphide dihydrotrypanothione, T(SH)2  
, (N1, N8-6w-glutathionylspermidine), is capable of undergoing rapid nonenzymatic 
disulphide exchange with intracellular disulphides, including glutathione.
This enzyme, therefore serves the function of glutathione reductase in 
trypanosomatid parasites and is essential to reduce parasitic GSSG. Thus it represents 
their main defence against reactive oxygen species. Trypanothione is maintained in the 
reduced state by the NADPH-dependent enzyme trypanothione reductase15"17.
Trypanosomes also lack the enzymes catalase and glutathionyl peroxidase, which in 
other organisms degrade H2O2 and other organic peroxidases. The NADPH- 
dependent flavoprotein trypanothione reductase (TR) reduces T(S)2  to T(SH)2 , 
providing an intracellular reducing environment in these parasites, substituting for the 
glutathione / GR redox system found in the mammalian host15"17. It is thought that 
trypanothione may function in the trypanosomatid glutathione catalysed reaction as 
shown in figure 6 12.
(i) T(S)2 + NADPH + H+ — T(SH)2 + NADP+
(ii) T(SH)2 + GSSG > T(S)2 + 2 GSH
















Trypanothione Disulphide (TSj) Trypanothione PXSHy
(TR=Trypanothione Reductase)
Scheme 2
As discussed above, many of the antioxidant functions of trypanothione result 
in the formation o f T(S)2  and so inhibition of the reduction of the disulphide is a 
principle target for drug design.
• Mechanism of Action :
Both GSSG and GSH contain a cysteine residue which undergoes reduction or 
oxidation during the cycle catalysed by GR. Catalysis takes place in such 
a way that transfer of reduction equivalents is mediated by the flavin ring9.
In (1) we have the closed disulphide bridge between residues Cys 58 and Cys 63.
16
The reduction equivalents 
are carried to the disulphide 
bridge of the protein with the 
result that the dithiol is formed, 
as shown in (2) o f scheme 3.
NADPH is released resulting in 
a charge transfer interaction 
between the thiolate form of 
Cys 63 and the flavin ring (3).
After binding of GSSG a series 
o f thiol exchanges leads to the release o f two molecules o f GSH and the reoxidation 
o f the active site dithiol to give the disulphide. This completes the catalytic cycle 9’14.
TR is also an FAD- and NADPH-dependent disulphide reductase and hence 
shares many physical and chemical properties with GR, the closely related host 
enzyme. The most important difference between the two reductases is that TR reduces 
only the glutathionyl-spermidine conjugate, whereas GR is specific for glutathione 
disulphide9. Apart from this the mechanism of reduction is essentially the same. 
Alignment and overlay o f the primary sequence of trypanothione reductase with that o f 
human erythrocyte glutathione reductase reveal 41 % amino acid sequence identity, 




• Inhibitors of GR and TR :
There are already various methods of inhibiting the biosynthesis of the two 
reductases14, but we are concerned with their inhibition of the action. Many pathogen 
proteins such as TR, GR, the enzymes of the Aids virus, and ribonucleotide reductase 
of the herpes simplex virus, are obligatory dimers. Studies have shown that each 
monomer unit by itself is inactive, and so enzyme inhibitors of TR and GR could be 
aimed at affecting the dimerization process, and research into this area is covered in 
several reviews1’3,18.
It has also been shown that trivalent arsenical drugs, such as melarsen oxide, 
are potent inhibitors of the NADPH-reduced TR in vitro, it was thought by reaction 
with the cysteine residues in the active site of the enzyme19. However, it has been 
discovered that the arsenical reacts primarily with intracellular T(SH)2  to form a stable 
dithioarsane adduct, MelT, and in turn it is this adduct which is a competitive inhibitor 
of TR. Drugs such as Melarsoprol are still extensively used in the treatment of the 
latter stages of human African trypanosomiasis, however, the drug itself is thought to 
be responsible for the deaths of 4 - 8 % of patients by causing an arsenical-induced 
encephalopathy15,19.
Their are drugs that can inhibit both GR and TR such as the cytostatic agent
l,3-bis-(2-chloroethyl)-l-nitroso urea (BCNU), which covalently inhibits GR but also 
inhibits TR15.
18
As mentioned before, modifications to disulphide bridges have been made 
before in the design o f inhibitors o f TR, (page 5), and these compounds were selective 
competitive inhibitors o f the enzyme 4. It is proposed that we should inhibit GR and 
TR by synthesising analogues o f glutathione disulphide and trypanothione, replacing 
the S-S bond between cysteine residues with an allene surrogate, (fig 7).
It is hoped that these compounds will be competitive inhibitors o f the two 
respective flavoenzymes by fitting into and blocking the active site o f the enzyme. It is 
also possible that they will act as suicide inhibitors, if the allene is attacked by an 
enzyme active-site nucleophile forming an extremely long-lasting complex with the 





Biological Target No.2 : 
creation o f antibodies with disulphide bond formation /  isomerisation / cleavage
activity
Protein disulphides are present in large concentration in extracellular fluids, yet 
little is known regarding mechanisms that generate and maintain significant levels of 
disulphide in the strong reducing environment present in mammalian cells. Further 
work on the nature of enzymes maintaining cellular thiol:disulphide balance may 
eventually reveal how this potential is modulated in vivo. It is the aim of this part of 
the project raise antibodies that not only inhibit the action of potentially harmful 
proteins, but also that catalyse the formation, disassembly and rearrangement of 
disulphide bonds.
~ • Introduction to antibodies
Antibodies are the bodies defence mechanism against invading organisms. In 
most biological systems like hormones and receptors, and enzymes and substrates, 
recognition usually occurs through fairly accurate complementarity in shape allowing 
the ligands to approach so close to each other as to permit the normal intermolecular 
forces to become relatively strong. Selective recognition is achieved through a large 
number of weak bonding interactions involving hydrogen bonds, van der Waals, 
electrostatic interactions, and solvent effects that chemists do not yet fully understand 
and are still far from being able to mimic 8’20’21.
20
The molecules in the micro-organisms which evoke and react with antibodies 
are called antigens. Antibodies are formed before antigen is ever seen and they are 
selected for by the antigen. A lymphocyte makes only one antibody and places it on its 
outer surface to act as a receptor. When an antigen enters the body it is confronted by 
a dazzling array of lymphocytes all bearing different antibodies. The antigen will only 
bind to those receptors with which it makes a good fit.
Lymphocytes whose receptors have bound antigen receive a triggering signal 
and develop into antibody-forming plasma cells, and since the lymphocytes are 
programmed to make only one antibody, that secreted by the plasma cell will be 
identical with that originally acting as the lymphocytes receptor, i.e. it will bind well to 
the antigen8,21.
Molecules o f <5-kD are rarely antigenic. Yet, when haptens (a well-defined 
small organic group to which antibodies can be formed), such as the 2,4-dinitrophenyl 
(DNP) group (fig. 8 ), are covalently attached to a carrier protein such as bovine serum 
albumin and then injected into an animal, the animal produces antibodies that bind to 
the hapten in the absence of the carrier. Without this carrier protein the hapten- 
antibody complex fails to stimulate antibody production21.








With the aid of mechanistic and synthetic chemistry in combination with the 
highly evolved synthetic and selection processes of nature, the vast network of 
molecules and cells of the immune system has been tapped to produce antibodies with 
a new function - Catalytic Antibodies. Because antibodies can be generated that 
selectively bind almost any molecule o f interest, this new technology offers the 
potential to tailor-make highly selective catalysts for applications in biology, chemistry, 
and medicine21.
Although there was speculation about antibody catalysis it was not until the 
mid 1980’s that catalytic antibodies were discovered. Since that time the number and 
diversity of antibody catalysed reactions has been growing rapidly as new strategies are 
being developed for their generation. Catalytic antibodies are characterised by high 
substrate specificity, share many mechanistic features with enzymes, including catalysis 
by proximity, transition state stabilisation, and covalent catalysis, and in some cases 
their rates are comparable to enzymes21.
One of the obvious advantages of using antibodies as a starting point to make 
highly selective catalysts is that the problem of engineering substrate specificity is 
solved by nature. Also, once an approach has been developed the catalytic antibody 
can be “tuned” by appropriate modifications to hapten structure.
22
The chemical potential of the immune system was underscored in 1986, when 
the research groups of Schultz and Lemer showed that antibodies could selectively 
catalyse the hydrolysis of carbonates and esters, respectively21. Since that time, 
antibodies have been generated that catalyse a wide array of chemical reactions ranging 
from pericyclic reactions to peptide bond cleavage. Typically the antibody-catalysed 
reactions proceed with rates 1 0 3 - 1 0 6 fold fester than the uncatalysed reactions.
These antibodies catalyse reactions in a number of ways21. They can act as 
entropic traps where the binding energy of the antibody freezes out the rotational and 
translational degrees of freedom necessary to form the activated complex therefore 
lowering the AS^ of the reaction. Catalytic antibodies can also stabilise the rate- 
determining transition state of a reaction, where the antibody combining sites are 
sterically and electronically complementary to the transition state configuration, again 
using binding energy to stabilise the unstable transition state. Catalytic antibodies 
which act in this way can be raised using a hapten which mimics the high energy 
transition state for a particular reaction therefore generating antibodies with the 
required antigen-binding site characteristics.
• Synthetic Targets
The essential idea underlying antibody catalysis is to anticipate the mechanism 
of a chemical reaction and then rely on binding energy to lower activation energy along 
the reaction co-ordinate2U2. Such catalysis depends upon the extent to which the 
hapten models critical features of the rate-determining transition state.
23
In our case we require a hapten that mimics the transition state that disulphide 
bonds go through on formation and cleavage, and it is hoped that our allene is just that 
since it is slightly longer than the native sulphur-sulphur bond. In other words we need 
to synthesise a peptide with the allene incorporated into its structure in replacement for 
a disulphide bond. In this respect it was decided to combine biological targets 1 and 2 
in that the synthetic targets, Le. the mimics of glutathione / trypanothione reductases 
(figure 9), could be used for both aspects of the project.
Once the haptens had been synthesised they could be covalently attached to a 
carrier such as bovine serum albumin, and used to raise antibodies that selectively bind 
it. It is then hoped that these antibodies would bind the native peptides in the absence 
of a carrier and catalyse the reactions of disulphide bond formation and cleavage. 
Disulphide exchange should occur as well since the activation energy of the disulphide 
intermediate is lowered by strong binding between the peptide and the antibody. The 
antibodies would be raised by either injecting the hapten-carrier conjugate into an 
animal, or by use of combinational antibody libraries. The antibody could then be 









Biological Target No. 3 :
Use o f the allenic substitution as a redox stable linkage in C? symmetric inhibitors
o f HIV protease
•  Introduction :
The pandemic spread of acquired immunodeficiency syndrome (AIDS) and the 
discovery of its causative agent human immunodeficiency virus (HTV), a retrovirus, 
has lead to an unprecedented scientific and clinical effort to understand and combat 
this lethal disease. HTV is a retrovirus and two genetically distinct subtypes, HIV-1 
and HTV-2, have been characterised23. Infection by the virus, which targets monocytes 
expressing surface CD4 receptors, eventually produces profound defects in cell- 
mediated immunity. Over time infection leads to severe depletion of CD4+ - T- 
lymphocytes resulting in opportunistic infections, neurological and neoplastic disease, 
and ultimately death23. Original W.H.O. predictions that six million people will be 
affected with the AIDS virus by the year 2000 were wildly inaccurate and the number 
is already over 4 times that24,25.
The replication of numerous plant and animal viruses depends on the specific 
action of virus encoded proteases. The assembly of infectious progeny virus from these 
precursors requires proteolysis of specific peptide bonds between the protein domains.
HIV-1 Protease
HIV-1, like other retroviruses, encodes a highly specific protease which is 
uniquely responsible for the post-translational cleavage of viral gag and gag-pol 
polyproteins23"25. It was recognised that the highly conserved triad Asp-Thr(Ser)-Gly, 
found in putative retroviral protease sequences was homologous to the catalytic site of 
proteases belonging to the aspartic acid family and that HIV-1 protease was of this 
class. While the catalytic triad occurs twice in archetypal aspartic acid proteases like 
pepsin and renin, it only occurs once in retroviral proteases giving rise to the 
observation that retroviral proteases exist as homodimers. The homodimeric nature of 
the HIV-1 protease has been confirmed by X-ray crystallographic and biochemical 
analysis25,26. Assembly of the two 99 amino acid HIV-1 monomers results in a dimer 
and generates an active site at the interface of the subunits. Each monomer contributes 
half o f the active site which includes two catalytic aspartate residues as well as the 
threonine/serine and glycine residues24"26.
Dimer formation generates not only the catalytic centre but also the extended 
substrate binding pocket. This substrate binding pocket is formed in a region along the 
central axis of the symmetric homodimer. Eight individual subsites are formed along 
the length of the enzyme surface and are designed to accommodate substrate amino 
acid side chains. Substrate binding in the subsites is governed largely by an ability to 
form stabilising van der Waals interactions between substrate amino acid side chains 
and enzyme amino acid side chains lining the subsites26.
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The HIV-1 protease is essential for the assembly and maturation of infection 
virions, and mutation in the active site renders the protease inactive, resulting in 
immature, non-infectious virus particles. Replacement of the catalytically active 
aspartic acid residues by either alanine, asparagine or threonine, by site-directed 
mutagenesis renders the enzyme inactive24-26.
The pivotal role of the protease in the post-translational processing of viral 
proteins makes it a prime target for drug design. Agents that specifically and 
effectively inhibit the hydrolytic activity of the protease may serve as powerful antiviral 
pharmaceuticals.
• Inhibitors:
The generation of a high energy, tetrahedral diol, (I), from a low energy, 
trigonal amide constitutes a key step in aspartic protease catalysis, scheme 4 25,27.
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Scheme 4
One of the classical strategies for designing enzyme inhibitors is the incorporation of a 
transition state mimic into substrate analogues. This can be applied to the design of 
HIV protease inhibitors by replacing the substrate scissile amide bond with a non- 
hydrolysable transition state isostere.
To either side of this amide bond are the substrate binding pockets (S,Sl / S i, 
Si1 etc.) that line the substrate-binding groove, and apart from optimising the fitting of 
inhibitor amino acid side chains into their corresponding binding pockets, inhibitor 
design must also take into account hydrogen bonding and electrostatic interactions 
which occur along the groove. A list of possible hydrolytically stable dipeptide isostere 
replacements for the scissile bond are shown below in table 1 24’25’28. These analogues 
mimic the geometry of the tetrahedral intermediate in peptide hydrolysis.
(V) (VI) (VII)
Table 1
While many of these peptidomimetic inhibitors posses potent antiviral activity 
in vitro they suffer from the same pharmacological problems that many 
peptidomimetics suffer from. A major strategy to reduce pharmacological problems is 
to develop inhibitors which either structurally or functionally mimic bioactive peptides 
but have either reduced or no peptidic character. An increasing number of reported 
non-peptidic HTV protease inhibitors which have been discovered through screening 
(of natural products and libraries of synthetic compounds), or from structural-based 
design founded upon crystal structures of HIV protease / inhibitor complexes24. The 
distinct features of this series of compounds are the low molecular weight and 
relatively non-peptide nature, containing only a single amino acid in most cases.
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An alternative to transition state mimics is the replacement of the water 
molecule which bridges the P2 and Pi* carbonyls of the inhibitor to the NH residues of 
Ileso from each monomer flap of the enzyme, while the inhibitor hydroxyls bind to the 
Asp25 residues in the active site, (fig. 10)25’27. The hydrogen binding to this water 
molecule help the two conformationaly flexible flaps to close around the substrate.
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It has been suggested that there would be a significant entropy gain if this water 
molecule could be replaced by an inhibitor component, and a number of cyclic 
inhibitors have been designed using computer modelling techniques2S.
However, one of the most promising reduced-peptide approaches utilises the 
symmetry characteristics of the protease. As mentioned previously HIV-1 protease 
was shown by X-ray crystallography to be a homodimer, and this also showed that the 
native enzyme adopts a conformation in which a two-fold symmetry axis extends 
through the active site 24’29‘32. It therefore might also be desirable to include this 
C2-symmetry through the centre of the inhibitors.
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In addition, as symmetric inhibitors are less peptide-like than the peptide-based 
inhibitors using the natural substrate sequences in conjunction with the transition-state 
analogue concept, the stability of symmetric inhibitors in vivo would be higher than for 
non-symmetric ones. Moreover, symmetric inhibitors should confer high specificity for 
retroviral proteases over related mammalian aspartic proteases, whose substrate 
binding sites are less symmetric.
The enzymes C2-axis lies between and perpendicular to the two catalytic 
aspartate residues in the active site. The X-ray crystal structure of HTV-1 protease 
shows that the so called Si and Si’ subsites are related by a C2-symmetry operation and 
are thus structurally identical (or nearly identical)24,29’30. Some tactics are to divide the 
design problem into two separate stages, the design of a central unit and the design of 
the two identical terminal groups. These three units could then be coupled together by 
amide linkages. This design must satisfy two major constraints.
First, there must be a productive, symmetric interaction between the inhibitor 
and the enzyme, and for this to occur their C2-axes must coincide. Second, the 
inhibitor should be able to fill the hydrophobic subsites that normally interact with the 
side chains of the asymmetric peptide substrate.
However, careful examination of the substrate binding region indicates that 
only the Pi and P2 substituents would likely be buried in the subsites of the enzyme.
The original design of a C2-symmetric inhibitor from the tetrahedral intermediate for 
cleavage of the substrate hinged on three operations (figure 1 1 ).
First, a hypothetical axis of symmetry in the substrate is defined based on the C2-axis 
-  o f the enzyme. Modelling experiments and the feet that the catalytically active 
aspartate residues reside close to the C2-axis of the enzyme lead to the placement of 
the symmetry axis either on the carbonyl carbon undergoing cleavage or through the 
middle of the scissile bond. Second, one “half’ of the substrate is arbitrarily deleted. 
Deletion of the P’ region is guided by the greater importance of the P region 
previously observed for the binding of renin inhibitors29.
Application of these operations gives rise to such inhibitors as (VIII) and (IX) 
shown below, both of which were potent inhibitors of HIV-1 protease activity. There 
are many variations of C2-symmetric inhibitors, with either different terminal groups or 














It is one of the aims of this project to synthesise a C2-symmetric inhibitor with 









To be able to include the allene surrogate into a peptide sequence, for example 
to enable its use as a hapten, we require a basic subunit that can be used as a building 
block and then build the peptide around this. It is proposed that the allene bis-ammo 
acid ( 1 ) be synthesised as a single diastereomer.
NB
(1)
Once we have (1) the amino and carboxylic acid functionalities can be 
protected, to give (2 ), and derivatised products can, in turn, be constructed from this 






Preparation of allenyl £fo-amino acids :
In recent years, a steadily increasing demand for sizeable quantities of a-amino 
acids has developed because of their extensive employment in biochemical, nutritional, 
microbiological, and tissue culture research, in addition to their widespread use as 
supplements for natural and processed foods33. Other than isolating amino acids from 
natural sources a number of practical chemical syntheses are presently known which 
permit ready access to a host of a-amino acids on both an industrial and laboratory 
scale.
The synthesis of a-amino acids at the bench is an active field because of the 
demand for specifically labelled, unnatural amino acids. The need is almost always for a 
homochiral product, so assembly of the target without regard to a-chirality must be 
followed by resolution; alternatively an asymmetric synthesis may be employed or the 
conversion of a freely available homochiral compound to the required a-amino acid 
must be achieved.
As yet there is no reported synthetic procedure for allenyl ^w-amino acids. 
Therefore we have to use known methods for amino acid synthesis coupled with 
known methods for allene formation. General methods are available for the preparation 
of racemic a-amino acids. Many o f these methods were developed in the early days of 
amino acid chemistry, but still retain their importance.
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These general methods33-35, shown below, include the DFAM method, scheme 
1; displacement reactions, scheme 2; the Strecker synthesis, scheme 3; and synthesis 
through hydantoins, scheme 4.
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Unfortunately it is highly likely that some of these methods and many of the 
reagents employed in these approaches are not compatible with the allene unit. For 
example, the Strecker synthesis requires blocking groups in the 2-position since
3,4-dienals tend to rearrange to 2,4-dienals34. The products of these reactions are also 
racemic, thus calling for tedious and time consuming resolution and separation 
techniques which can be avoided by the use of more attractive asymmetric and 
enantiospecific routes.
SchQllkopf and collaborators36'39 have devised a versatile and useful method for 
the preparation of a large variety of amino acids based on the metallation and 
subsequent alkylation of £ w-lactim ethers. The general protocol involves peptide 
coupling of two amino acids, piperazinedione formation and 6/s-lactim ether formation 
with trimethyloxonium tetrafluoroborate. Metallation with n-BuLi in THF at low 
temperature followed by electrophilic quench furnishes the homologated 6/s-lactim 
ethers. The electrophile is considered to add anti- (fig.l) to the methyl group in a 
highly stereoselective fashion with typical diastereomeric excesses of greater than 





By far the most extensively studied bis-lactim ether is that derived from 
L-valine and glycine. As shown in scheme 5 below, L-valine is converted into the 
N-carboxyanhydride (3) and condensed with glycine ethyl ester. Heating the dipeptide 
(4) furnishes cyclo-L-Val-Gly (5) which is, in turn, converted into the Z?/s-lactim ether 
(6). This reagent has become the most widely used glycine template and is now 
commercially available in both enantiomeric forms.
As mentioned above, metallation of the 6/s-lactim ether with butyl-lithiufti in 
THF at low temperature followed by alkylation with a variety of electrophiles proceeds 
with a high degree of stereoselectivity furnishing the anti-products (7). Hydrolytic 
cleavage of the heterocycle with dilute HC1 at ambient temperature furnishes the new 
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► L-Val-OMe + X
(8)
H CB2R
Where RCB2X = the dimesylated allene 
Scheme 5
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New methods for the synthesis of enantiomerically pure a-amino acids are 
constantly being explored and much recent progress has been made in the use of 
fimctionalised zinc reagents as alanine P-anion equivalents40"43, figure 2.
© v^^N H B oc
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Fig. 2
The organometallic reagent shown in figure 3 is a synthetic equivalent for the 
nucleophilic alanine synthon shown in figure 2, and couples efficiently with organic 
electrophiles under catalytic conditions to give enantiomerically pure, protected amino 
acid derivatives. This area is covered in greater detail later in this report.
IZn
Figure 3
As mentioned earlier there is no reported synthetic procedure for allenyl bis- 
amino acids and that we therefore have to use known methods for amino acid synthesis 
coupled with known methods for allene formation. This can be done by either 
assembling the allene structure first and then affixing the amino acid sections, or by 
attached the amino acid units and then building in the allene. Over the duration o f this 
project three distinct alternatives were attempted.
1. Synthesis of a basic allene unit via elimination from a halo-alkene, then activation of 
this compound followed by nucleophilic substitution by a suitable amino acid 
equivalent.
2. Formation of a 6/s-amino acid / alkene compound followed by allene synthesis via a 
cyclo-propanyl carbene.
3. Formation of an acetylene / amino acid subunit followed again by nucleophilic 
substitution using by a suitable amino acid equivalent to give the allene.
Each of these methods will now be discussed in turn.
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M ethod 1 - Elimination from halo-alkene followed by nucleophilic substitution :
It was decided that the best precursor for the activation of the allene for 
nucleophilic substitution was the allenic diol (9).
A survey of the literature revealed that the allenic diol (9) was an unknown 
compound. A facile synthesis for this important starting material was therefore
synthesis of allenic esters, scheme (6), involving the elimination of HC1 from 
dimethyl-3-chloropent-2-ene-l,5-dioate (11), itself synthesised from the cheap and 
~readily available starting material diethyl pent-3-one-l,5-dioate (10). This method gave 
easy access, with good yield, to the allene (12). The products (11) and (12) were 
purified by distillation, with higher yields being obtained by performing the process in 
small batches. The allene required storage at low temperature to minimise 
polymerisation processes, detected by increase in viscosity and coloration.
(9)
required. We initially attempted a known procedure laid out by Bryson et a t4 for the
c 2h5o 2c .: ^ J I ^ / c o 2c 2h 5 - ) - »  c h 3o 2c ^ A ^ c o 2c h 3 - - (l°  »  
(10) (11)
(i) PC15 , 40°C , 1 hour; (ii) NEt3, THF, 0°C
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The strong i.r. absorption detected at 1960 cm'1 was characteristic of the 
allenic antisymmetric stretch. In addition the extreme low field position of the allene 
central carbon was identified by 13C n.m.r. spectroscopy at 6 220 ppm.
Having obtained (12) in reasonable yield, a suitable method of reduction was 
sought. Initial attempts by treatment with LiAlH* were unsuccessful The reaction was 
performed in diethyl ether, at various sub-zero temperatures but on each occasion no 
allene-containing product was detected. However, a strong OH peak was observed in 
the product and the infra red spectrum showed an absence of any carbonyl bands. 
Further examination by 1 H n.m.r. spectroscopy suggested that a mixture of 1,5- 
pentanediol and pent-2,4-dienol products had been formed, possibly by the method 
shown in figure 4. Reduction by borane in THF at 0°C 45,46 also gave the same results 




Although it is generally accepted that sodium borohydride is not useful for the 
reduction of carboxylic esters, cases have been reported in the literature of esters 
being reduced to primary alcohols47. Here it seems a neighbouring group plays some 
sort o f role. Attempts to reduce the ester by using NaBH* in aqueous ethanol resulted 
in the successful reduction of the ester groups, but unfortunately the allene unit was 
also reduced. Successful reduction was finally achieved by using diisobutylaluminium 
hydride (Dibal-H) as the reducing agent, (scheme 7).
Many different conditions were explored and the best result was obtained when 
the reaction was carried out in toluene at 0°c. Decomposition of the aluminium salts 
was best achieved by treatment of the intermediate aluminium complex with potassium 





Use ofMeOH/H20  as the initial treatment for the decomposition of the 
aluminium salts resulted in a lower yield of product. The diol was extremely water 
soluble and the continuous extraction had to be carried out for as long as a week to 
obtain a reasonable yield. This was rather tedious, but it proved that the diol was stable 
in aqueous conditions
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Purification was best effected by column chromatography. Use of distillation, 
even of small batches, resulted in extensive polymerisation and decomposition of the 
diol; this also occurred on standing at RT, but was suppressed by storage at low 
temperature.
The identity of (9) was confirmed from spectral data, which showed strong 
bands in the Lr. spectrum at 3600-3100 cm' 1 (OH) and 1970 cm' 1 (central allenic 
carbon), with no carbonyl absorption detected. In the lH n.m.r. spectrum no spin-spin 
coupling was detected from the C-2 to C-4 proton or from C-l to C-5 protons due to 
the symmetry of the molecule (figure 5). The coupling constant of C-l protons to 
those of the adjacent C-2 and the long range proton-proton coupling, 5J (H-H) to C-4 
were identical, giving rise to an apparent triplet at 5-4.16 ppm. The protons of 
C-2 and C-5 are isochrons and resonate as a triplet at 5 5.51 ppm. The allenic central 
carbon was evident in the 13C n.m.r. spectrum at 5 202.5 ppm. Furthermore, mass
spectrometric analysis by chemical ionisation (C.I.) revealed a weak (M+l)+ peak at
m/z 101 with an intense signal at m/z 83 (M+1-H20 )+. Due to decomposition of the 




Attempts to Activate the Allene Moiety for Alleviation :
We now required activation of the diol ready for attack by a suitable 
nucleophile, for example Schdllkopf s reagent, leading to the desired allenic amino 
acids. An emphasis had recently been placed on accessing a,a-disubstituted amino 
acids, and on the formal ‘double derivatization’ of a glycine template 48,49. Thus it was 
initially decided to activate both hydroxy groups and displace them both in the same 
step. Mono-protection would eventually have to be carried out as this would enable us 
to synthesise allenic compounds with different amino acid sidechains. On the other 
hand activating both hydroxy groups prior to alkylation would only allow us to make 
symmetric compounds.
Attempts at direct bromination by treating the diol with triphenylphosphite dibromide 
resulted in the disruption of the allene unit, while attempts to obtain the ditosylated 
product, by treatment with tosyl chloride in pyridine, also foiled resulting in a mixture 
of tosylated and vinylic material devoid of any allenic product. It would seem that 
activation of the alcohol moieties has increased the sensitivity of the allene towards 
elimination. It has been shown that nucleophilic addition to allenes only takes place 
readily when there is activation by an electron-withdrawing substituent conjugated 
with one of the double bonds (Michael type addition) or through a neighbouring group 
effect as in the reduction of allenic alcohols (figure 4). Indeed, similar work carried out 
by Trost et al. 50 on the activation of p-hydroxy allenes showed that attempts at 
tosylation and bromination resulted in the exclusive formation of the eliminated 
product, (scheme 8 ).
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Scheme 8
However, in our hands attempts to activate the allenic diol (9) by formation of 
the dimesylated adduct (13), via reaction with methanesulphonyl chloride in dry DCM 





The i.r. spectrum of the product revealed the absence of the OH band and the 
appearance of signals at 1340 and 1160 cm'1, due to the sulphonate ester. Presence of 
this group was further revealed by the methyl singlet at 5 1.05 ppm in the *H n.m .r., 
and at 8  38.3 ppm in the 13C n.m.r. spectra. The allene was identified by the usual 
characteristic signals in the Lr. and 13C n.m.r. Attempts to purify the product (13) by 
column chromatography resulted in its decomposition. It is possible that the failure of 
the tosylation reactions could be due to the differences in mechanism between 
tosylation and mesylation.
The dimesylated compound (13) was found to be very unstable and 
decomposition occurred even when stored at low temperature under an inert gas. Due 
to this instability a satisfactory elemental analysis and a mass spectrum were not 
obtained. None of the nucleophilic reactions tried so far with this substrate have been 
successful. V/ith other allenes that do react we consider that attack at the central 
carbon is inhibited by excess electron density donated from the two terminal carbons of 
the allene unit. For (13) it is possible that the two mesylate groups are drawing enough 
electron density away to activate attack on the central carbon and this may be 
responsible for this compounds lability.
For this reason emphasis was switched to the mono-protected hydroxy 
compound. The protection of one hydroxy group was carried out using t- 
butyldiphenylsilyl chloride (f-BDPSiCl). This reagent was chosen to form the /-BDPSi 
ether over related silyl and butyl ethers because such derivatives are easier to form and 
show compatibility with a variety of conditions51. For example they are moderately 
stable to acid hydrolysis. This stability is desirable if acid hydrolysis is required to yield 
the amino acid moiety at the other C-terminus of the allene unit. However, smooth 
cleavage is effected by treatment with fluoride ion.
The formation o f the mono-/-BDPSi ether was initially attempted by the 
treatment of (9) with f-BDPSiCl and NaH in THF. However, after several attempts, no 
allenic product could be detected and hence the procedure was abandoned. However, 
the desired compound (14) was obtained by use of imidazole in place of NaH 
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All spectral data were consistent with the desired product. A hydroxyl band 
was present in the Lr. spectrum at 3600-3100 cm'1, with additional bands at 1100 and 
820 cm' 1 (Si-O-C). The presence of the f-BDPSi ether was further indicated by /-Bu 
and aromatic signals in the !H and 13C n.m.r. spectra.
The mono-protection renders loss of symmetry, and this was shown by the !H 
n.mr. spectrum which revealed a double doublet at 8  4.08 and 4.25 ppm for the 
resonances of the protons of the hydroxy- and silyloxy-methine units respectively, due 
to 3J (H-H) and 5J (H-H) coupling in each case. Each allenic proton was now 
differentiated giving rise to a complex signal. Mass spectrometry (C.I.) revealed a 
major ion at m/z 321 due to loss of H2O from the molecular species, in addition to a 
(M+l)+ peak at m/z 339. The compound (14) was more stable than the non- 
functionalised allenic diol and polymerisation no longer took place.
The mono-protected allene (14) was then mesylated in the same manner as the 
diol to furnish the mono-protected mono-mesylated adduct (15), scheme 11. It was 
hoped that attack by a suitable nucleophile would then furnish the allenic amino acid.
Scheme 11
As SchSlIkopf s reagent is very expensive it was decided to employ a cheaper 
nucleophilic agent initially to work out the best possible strategy. Many papers report 
that the benzylidene derivative of glycine ethyl ester (17) can be used in mono- or 
sequential reactions leading to a very simple synthesis of a-amino esters and 
acids48,49’52'54. Although the products of such a reaction would be a mixture of 
diastereomers in our case this should, if successful, validate our methodology prior to 
using the SchQllkopf procedure. The benzylidene glycine ethyl ester (17) was 
synthesised from glycine ethyl ester hydrochloride (16) and benzaldehyde, as shown in 




The relatively high acidity of (17) permits formation of the corresponding 
carbanion not only with strong bases like lithium diisopropylamide, which could be 
detrimental to the allene, but also with weaker bases such as potassium ter/-butoxide49.
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It is also worth noting that the simple ethyl ester is much more stable than was 
originally claimed and it can be stored at low temperature for several months49. 
However, it turned out that the benzaldehyde starting material could not be removed 
from the final product, this meant that the resulting amino acid was impure. All 
attempts to remove the aldehyde, either by column chromatography or by complexing 
with sodium bisulphite, resulted in the degradation of the SchifFs base.
To overcome this problem the diphenyl glycine derivative (18) was synthesised. 
The first attempt in which benzaldehyde was replaced with benzophenone foiled. This 
is due presumably to the lower reactivity of benzophenone, but when the reaction was 
carried out by stirring glycine ethyl ester hydrochloride and benzophenone imine 
together at room temperature for 24 hours, excellent yields of the desired compound 
were obtained, (scheme 13)54.
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Using the benzylidene glycine ethyl ester it should be possible to obtain the 
mono-protected amino ester (19) by the route shown for the silyl-protected ether in 
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Unfortunately all attempts to react the allene mesylate with the carbaniou of 
(18) failed. The allene appeared to decompose and only presence of the silyl protection 
group could be detected by spectroscopic methods. It is possible that elimination is 
taking place and that volatile products were lost when the solvent was removed under 
vacuum, or that nucleophilic attack is now focused upon the more electron deficient 
central carbon of the allene. As an alternative approach we next turned to a palladium 
catalysed reaction as Cazes and co-workers have developed a palladium catalysed 
m coupling of the glycinate anion of (18) with allenic phosphates 5S.
Using this methodology we decided to make the allenic phosphate (20) in a one 
step reaction from the mono-protected alcohol by reaction with diethyl 
chlorophosphate in the presence of pyridine, (scheme 15).
o
Ph |i Ph
, \  cK \
—|—Si—O
Ph
/  \ _________________Pyridine
>H — O—P— (OEt)2
(14) (20)
Scheme 15
The structure of the phosphate (20) was confirmed by spectral data. The 
absorption band in the i.r. spectrum at 3600-3100 cm*1 (OH) of the starting material 
had disappeared but the peak for the central carbon of the allene unit at 1970 cm' 1 and 
the bands at 110 and 820 cm*1 (Si-O-C) were still present. In addition there were new 
peaks at 1277 cm*1 (P=0) and 1050-1020 cm*1 (P-O-CH2). The presence of the t- 
BDPSi ether was further confirmed by the t-Bu and aromatic signals in the !H- and 
13C-spectra. In the 1H- n.m.r. spectrum the methylene proton resonance next to the 
phosphate also showed coupling to the phosphorus, and a triplet at 5 1.3 ppm and 
quartet at 5 4.1 ppm indicated the presence of the ethyl ester groups of the phosphate. 
Finally mass spectrometry (FAB) revealed the expected (M+l)+ peak at m/z 475.
Transition metals, palladium in particular, have found widespread utility in 
catalysing a number of important organic chemical processes. Central to all these 
catalytic reactions is the ease with which organo-palladium compounds can undergo 
oxidative addition and reductive elimination reactions 56.
The use of palladium in allene chemistry is a type of allylic substitution. It is 
believed that the mechanism of the palladium catalysed substitution involves the initial 
co-ordination of palladium (0 ) to one of the double bonds, followed by an oxidative 
addition process to afford an intermediate r|3- allyl complex, (scheme 16). In the 
presence of phosphine, an equilibrium between a neutral and cationic complex results. 
The cationic complex is favoured by the use of bidentate phosphine ligands to which 
nucleophilic addition then takes place to one of the termini of the allylic unit to afford 
the palladium (0) complex of the product. Dissociation of the palladium (0) liberates 
















Allenic a-amino acids can be obtained by a three step sequence from the 
phosphates o f a-allenic alcohols:
(i) Palladium catalysed alkylation o f a Schiff base derived from glycine ester 
by the phosphate,
(ii) acidic hydrolysis o f the imine functionality
(iii) saponification o f the resulting amino ester.
As previously described, the phosphate (20) can be conveniently prepared from 
the mono-protected allenic alcohol (14), scheme 15, and it has been shown that similar 
phosphates react smoothly in THF at room temperature with the lithio-derivatives of 
benzylidene glycine esters. The reaction requires the presence o f a 4% catalytic system 
obtained by addition o f six molar equivalents o f triphenylphosphine to the stable 
palladium-bis(dibenzylideneacetone) complex [Pd(dba)2]. Under these conditions the 
starting material is completely consumed in two hours and the imino esters were 
obtained in acceptable yields56.
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The imine functionality can be easily removed by reaction with a dilute ethereal 
solution of hydrochloric acid to provide the amino ester after neutralisation. Treatment 
at room temperature of these amino esters with 1 M methanolic solution of sodium 
hydroxide, followed by chromatography on an acidic column leads to pure y-allenic a- 
amino acids with excellent yields. It appears that the allenic moiety is stable under the 
acidic or basic conditions used in the last two steps and that intramolecular attack by 
the amino or carboxylate groups did not occur56.
Thus, this palladium-catalysed process appears to be a good way for the 
preparation of diversely substituted y-allenic a-amino esters and acids from the readily 
available a-allenic alcohols, and so it was tried upon our substrate (2 0 ), as shown in 
scheme 17.
The data collected on the product shows that the reaction was a relative 
success. In the Lr. spectrum signals corresponding to the allenic system and the Si-O-C 
group are still present, but the phosphate peaks had disappeared. In addition to these, 
there are strong absorptions at 1730 cm' 1 (-C0-0-) and 1660 cm' 1 (C=N). In the 1H- 
n.m.r. spectrum the two allenic proton resonances are now in different environments to 
that of the starting material giving rise to two multiplets at 5 5.0 and 6  5.2 ppm.




Where R= t  - BDPSK>-CH2
(21)
Scheme 17
The silyloxy-methylene resonance now appear as a triplet at 8  4.33 ppm. The 
quartet for the OCH2 signals of the ester and the multiplet for the a-proton of the 
amino acid group overlap to give a complex signal at 8  4.15 ppm. The methylene 
protons that were adjacent to the phosphate are now no longer so deshielded and they 
resonate as a double triplet at 8  2.6 ppm. The 13C-n.m.r. spectrum still shows a peak at 
8  205 ppm for the central carbon of the allene unit and now also shows signals at 8  196 
ppm (-CO-O-) and 8  171 ppm (C=N).
Unfortunately, the best yield obtained for this reaction was only 15%, and 
changing the catalyst, solvent, or reaction conditions did not raise this yield. This, in 
conjunction with the poor yield for obtaining the allenic diol, made this route 
unfeasible as many more steps are still necessary in our proposed synthesis.
It was at this stage that we began to look for alternative routes. One of the 
main reasons for the failure, or low yield, of the alkylation steps seemed to be the 
instability of the allene. With this in mind we considered methods that would put the 
amino acid components into place first and then construct the allenic unit afterwards. 
Two alternative methods involving either a carbene or an acetylene are discussed 
below. Of the two alternatives the carbene route looked the most promising as it was 
simpler, cheaper, and involved the least number of steps. It was thus attempted first.
M ethod 2 - The carbene method :
The conversion of an alkene to an allene through dibromocyclopropane and 
carbene intermediates, first used in the early 1950’s, is probably one of the best general 
methods for introducing the allene group into an organic molecule5,62. An alkene is 
converted into the allene by what amounts to the insertion of a carbon atom between 
the two carbon atoms of the double bond. This is achieved in two stages:
1. Addition of a carbene to an olefin to give a cyclopropane derivative. The carbene is 
normally a dihalocarbene as halocarbenes are more stable and some side reactions 
are avoided 5’61,62. The carbene is usually generated by an a-elimination reaction in 
which a carbon atom looses a group without its electron pair, usually a proton, then 
a group with its electron pair, usually a halogen, as shown below 5’61,62.
1 -H ®  e . q ®H—C—Cl — R2C—Cl -------- ► R 2 C:
The singlet carbene adds to the double bond via a concerted cycloaddition reaction, 
and carbenes are so reactive that the reaction is practically simultaneous.
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2. The second stage involves the collapse of the cyclopropane to the allene. It was 
found that the treatment of certain gem-dibromocyclopropanes with either 
magnesium or sodium resulted in allene formation62, but the yields were poor (16- 
35%). Later it was discovered that the yields could be greatly increased, up to 90%,
We thus require the allyl bis-amino acid (23), shown in scheme 18. It was 
decided that the best starting material was the dibromoalkene (2 2 ) and that the 
benzophenone glycine template be used again as the amino acid template to avoid
waste of expensive stereoselective reagents. The palladium catalysed reaction between 
trans-l,4-dibromo-2-butene (22) and the glycine benzophenone imino ester (18) was 
carried out using the procedure laid out by Najera and Pedregal48, scheme 18, except 
substituting LDA for lithium hexamethyldisilazide (LHMDS). This afforded the 
masked 6 /s-amino acid (23) in good yield. The compound was purified by column 
chromatography.
by the treatment of the cyclopropane with alkyllithium reagents62.
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In the Lr spectrum there are strong peaks at 1730 cm' 1 (-CO-0-) and 1660 cm' 1 
(C=N), the alkene absorption was not evident as would be expected for a symmetric 
molecule. In the ^ -n m r. spectrum the signals of the methylene protons adjacent to 
the double bond have shitted to 8  2.55 ppm and become a multiplet. In addition the 
resonances expected for the ethyl protons of the esters are evident as are those for the 
phenyl groups. Furthermore, a F.A.B. accurate mass spectrum shows an intense 
(M+l)+ peak at 587, in accord with the required molecular formula: C38H38N2O4 .
There are a number o f methods for the formation of dibromocarbene, most 
involving some form of base and a halide. Early work on the conversion of olefins to 
allenes was carried out using the conversion of cyclooctene (26) to




Originally the reaction was carried out over two steps, with the carbene being 
generated from bromoform using either sodium hydroxide or potassium tert-butoxide, 
followed by treatment of the cyclopropano derivative with either methyl- or butyl- 
lithium. Greater overall yield was later achieved by carrying out the synthesis in a one- 
pot reaction by treating a fourfold excess o f cyclooctene with one equivalent of carbon 
tetrabromide and two equivalents of methyl lithium64.
The use of alkyl-lithium reagents in dibromocarbene formation or 
dehalogenation caused us concern over the stability o f (23) under such conditions. It is 
possible that the ester or imine functionalities might be attacked by the alkyllithium 
reagents, so samples of (23) in THF were treated with methyl- and butyl-lithium at 
room temperature and stirred for five hours. After work-up it was found that no 
reaction had taken place and starting material was recovered unaffected.
It was decided to carryout the reaction initially using the two step methodology 
so that we could isolate and characterise the cyclopropano derivative (24). We also 
decided to establish the reaction conditions with cyclooctene first, as a standard to 
prove to ourselves that we were carrying out the procedures correctly. Two different 
methods of carbene generation were chosen and the formation of the dibromocyclo 
-propane (24) was attempted using both of these:
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(a) A solution of cyclooctene and bromoform was treated dropwise with n-butyl 
lithium at -78°C under a nitrogen atmosphere. The yield of (27) was 60%.
(b) A solution of cyclooctene and bromoform in DCM was treated with aqueous 50% 
sodium hydroxide solution in the presence of benzyltriethylammonium chloride, a 
phase-transfer reagent. Compound (27) was isolated in 42% yield.
However, the success of these two methods with cyclooctene did not cany 
through to the reactions with alkene (23). In both cases no reaction involving the 
alkene (23) took place and starting material was recovered almost quantitatively.
Intent on forming the allene via the cyclopropano derivative of (23) it was 
decided to attempt the one-pot olefin to allene conversion following the procedure laid 
out by Untch, Martin, and Castellucci64. The reaction was again carried out using 
cyclooctene first as a model A solution of cyclooctene and carbon tetrabromide in 
diethyl ether, at -78°C under nitrogen atmosphere, was treated with 1.0 N methyl 
lithium (one equivalent) and the reaction mixture stirred for 30 minutes. The 
dibromocyclopropano derivative was not isolated but the reaction mixture was 
maintained at -60°C and another 1.1 equivalents of ethereal methyllithium was added. 
The solution was stirred for a further 30 minutes before being allowed to warm to 
room temperature. Work-up gave an oil which exhibited an unresolved n.m.r. 
spectrum This was, however shown by infra-red and boiling point to be
1,2-cyclononadiene (28), isolated in 57% yield. Unfortunately, in the ‘real experiment’ 
replacing cyclooctene with our alkene (23) and following the reaction conditions 
exactly as above led only to an almost quantitative recovery of starting alkene.
Since we know that the carbene is being formed from our model reactions with 
cyclooctene we can only assume that the alkene (23) is unreactive. A possible reason 
for this failure is that the base used to form the carbene is deprotonating the amino acid 
a-proton and not attacking the bromoform or carbontetrabromide. It was thought that 
this was unlikely since the pKa of the bromoform proton is 11.8 , whiie that for the 
amino acid is about 24 66.
In our hands adding further equivalents of base had no effect. However, in an 
attempt to confirm whether or not this was the problem the bromoform / methyl- 
lithium reaction with (23) was carried out again, but replacing the aqueous work-up 
with a deuterium oxide work-up. In this way we could detect the incorporation of 
deuterium into the starting material should deprotonation occur. However, no 
deuterium was detected by N.M.R. spectroscopy. Nevertheless we attempted to 
generate dichlorocarbene under neutral conditions, again as a model reaction between 













Mercuric chloride and two equivalents o f sodium trichloroacetate were heated 
in 1,2-dimethoxyethane for one hour. Work-up gave a clean white solid which was 
recrystallised from chloroform to give bis(trichloromethyl) mercury (29) in 51%.
The conditions for the formation of the cyclopropane (30) involve heating the alkene 
with bis(trichloromethyl) mercury to around 200°C 68, but since cyclooctene boils at 
145°C we only heated the two reagents to c.a. 130°C. No cyclopropane product was 
detected and this method was abandoned without being tried on (23).
At this stage it was decided to abandon the carbene route altogether and start 
on the third alternative: the nucleophilic substitution of acetylenes.
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M ethod 3 - The acetylene method :
This alternative route utilises the nucleophilic substitution of acetylenes of the 
general form shown below in scheme 21. It is by far the most versatile type of reaction 
for the formation of allenes, and often enables the conversion of acetylenes to allenes 
to be carried out in excellent yields5. Most nucleophiles (X) and most of the well 
known leaving groups (Y) may be applied.
\  \  /  ec-k:—c—  -------► c = c = c  + y
y )  t:X /  ^
Scheme 21
We yet again require the use of a nucleophilic amino acid template, however, 
~ using either Schollkopf s reagent or benzylidene derivatives would leave the resulting 
allene one carbon short between the allene unit and the amino acid terminus, and are 
both therefore inappropriate. We therefore require an alternative nucleophilic 
equivalent, and here we reverted to the use of the fimctionalised zinc reagents 
mentioned earlier in this report. The use of this alanine p-anion equivalent40"43, shown 









Jackson and his group have devised such a reagent, (31) shown in figure 7, and 





Normally this compound is activated prior to use by transmetallation since zinc 
reagents of this nature are relatively unreactive to most electrophiles due to the high 
covalent character of the carbon-zinc bond69,70. The empty low lying p-orbitals of zinc 
allow many transmetallation reactions with metallic salts to proceed with ease and this 
excellent transmetallation ability permits the conversion of organozinc reagents into a 
variety of new organometallic compounds69.
It was decided to follow the methodology laid out by Jackson’s group for the 
synthesis of (31) and use the reagent in attempts to construct our difimctionalised 
allene (l).The procedure for the formation of the iodide is shown below in scheme 22.
NH2 NH3+Tos NHC02










The starting material L-serine required the protection of both its amino and 
acid functionalities. a-Carboxy protection was carried out by the 4-toluenesulphonic 
acid catalysed esterification with benzyl alcohol to give the benzyl ester, isolated as the 
4-toluenesulphonate ester (33), in excellent yield. The free base was then generated in 
situ with sodium hydroxide during the a-amino protection step using Boc-anhydride to 
give (34). The free hydroxy-group was then activated by tosylation to give (35), 
which was treated with sodium iodide to give the iodide (36).
The organozinc reagent (31) was prepared by the direct insertion of zinc metal 
into the carbon-iodide bond of the protected iodo-serine compound (36). Direct 
metallation of an organic halide is known to be difficult, and transmetallation from 
organo-magnesium or organo-lithium precursors and a zinc halide is usually preferred. 
However, if zinc dust is activated with 1,2-dibromoethane and trimethylsilyl chloride 
prior to the addition of the organo-halide, then fast reaction rates are observed40,43’69. 
Studies showed that the rate of zinc insertion depends strongly on the nature of the 
organic moiety, the halide, the reaction conditions (solvent, temperature, and 
concentration), and the method of zinc activation69. For primary iodides the zinc 
insertion is complete within 2-3 hours at about 40°C, while secondary iodides react 
even fester, and a complete conversion to the alkyl zinc iodide is usually observed 
within an hour at 25°C. The zinc insertion shows remarkable functional group 
tolerance and most common organic functional groups can be present during the 
organozinc formation. Relatively acidic protons are tolerated during the preparation of 
organozinc halides, in strong contrast to the preparation o f organo-lithium and 




It is well known that various allylic compounds undergo facile palladium 
catalysed transformations via 7c-allylpalladium complexes and that nucleophilic attack 
on these complexes results in newly substituted alkenes56'58’60’72. In addition to allylic 
compounds nucleophilic substitution of propargylic substrates with a palladium 
catalyst, usually a versatile palladium (0) compound such as Pd(Ph3P)4 , is also possible 
giving rise to substituted allenes or alkynes, as seen in scheme 23 58,60’72.
Scheme 23
The chemoselectivity is dependent on the structure of the propargylic 
compound. The allene formation can be carried out most satisfactorily with a terminal 
alkyne bond while alkynes with an internal triple bond, or when Ri is a bulky group, 
are usually converted to substituted alkynes40’43’69.
All known palladium catalysed reactions o f alkynes are explained by the 
formation of either a a-allenyl palladium (II) complex (37) or a a-propargylpalladium 
(II) complex (38), resulting from the oxidative addition of palladium (0) to the 
propargylic substrate. Spectroscopic and microanalytical data provide good evidence 
for a structure in which an allenyl prop-2-ynylic moiety is a-bound to palladium72.
Scheme 24
When the leaving group (X) is a halide and R3 is hydrogen the reaction gives 
pure trans-(a-allenyl) bis (triphenylphosphine) palladium (II) halides (37). The 
acetylenic isomers (38) are obtained when R3 is a bulky group such as t-Bu or TMS , 
and when Ri and R2 are both hydrogen. The relative sizes of the R1.3 groups is 
important in deciding the regiochemistry72.
Leaving groups other than a halide can also be used to prepare the palladium 
(II) complexes, but salts like zinc chloride or lithium chloride must be present to allow 
the conversion to proceed69. Without these salts no reaction takes place. In the case 
where the leaving group (X) is an acetate group research showed that no acetate group 
was present in the cr-allenyl palladium complex72. Instead of the acetate group chlorine 
was present, being delivered by the zinc or lithium salt. Addition of a nucleophile 
displaces the leaving group (X) from the palladium complex which then undergoes 
reductive elimination to yield the newly substituted product. It is worth noting that the 
allene itself can also form complexes with palladium (0). One could imagine that 
through such complexes racemisation could occur. In some separate experiments it 
was found that optically active 1,3-diphenylpropadiene suffers from substantial 
racemisation when treated with 10 mol% of Pd[Ph3P]4  69. It is therefore highly possible 




Apart from the use of palladium as the second metal catalyst copper was also 
considered involving the formation of the zinc / copper reagent (39) 4<M3’69, scheme 25. 
The most efficient method of forming the zinc / copper couple is by an in situ reaction 
by the addition of the THF soluble copper (I) salt CuCN.2LiCl. The reaction of this 
salt with organozinc iodides is carried out at 0°C and takes about ten minutes. The use 
of lithium chloride to solubilise copper cyanide was found to facilitate the 
transmetallation allowing the use of milder conditions40-43,69.
^NHBoc 2LiCLCuCN .NHBoc
IZn  ► 2 UCLIZn(CN)Cu
§ THF =
C 02Bn q°C C 02Bn
(31) (39)
Scheme 25
Investigations show that these zinc / copper reagents follow the same 
mechanism of action as that for organocuprates40,69. The reaction sequence with 
propynyl halides and esters is analogous to the known mechanism for the palladium- 
catalysed alkylation. This type of catalytic reaction also shows high levels of 1,3- 
substitution. The reaction between the zinc/copper reagent (39) and chiral propargylic 
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(39)
In all cases reported so far, organocopper (I) mediated Sn2’ reactions with 
alkynes proceed with anti stereochemistry 69,/1. It is thought that a n-complex between 
the organocopper (I) fragment and the acetylenic compound occurs first; examples o f  
isolated Cu(I)-acetylene complexes are known. Subsequent elimination of the leaving 
group will take place only when the copper and leaving group moieties are in a mutual 
antiperiplanar disposition69,71, figure 8.
In this geometry not only is the interaction 
of the relevant copper (I) p and d orbitals 
with the acetylenic n and n systems 
important, but there is also additional 
donation from the copper 3d xz orbital into 
the carbon-leaving group antibonding a* 
orbital. It is this latter interaction that Figure 8
electronically initiates the decoupling of the leaving group. The directional specificity 
of this process guarantees that the 1,3-substitution occurs with a very high level o f anti 
stereoselectivity. As a result the unstable a-allenyl-copper (III) series is generated, 
which readily collapses by means of reductive elimination o f CuCN to give the allene. 
This latter step is assumed to proceed with complete retention o f configuration as is 
usually observed for such alkyl shifts from transition metal centres. Occurrence o f the 
transient Cu(III) intermediate has been corroborated in the past69.
NHBoc
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The choice of organometallic, solvent, leaving group and substrate, are all very 
important factors affecting the enantiomeric purity o f the allenes formed. Interestingly 
there seems to be less, or even no, problems regarding racemisation when the solvent 
is diethyl ether, whereas with THF fast racemisation of allenes by excess 
organocuprates has been reported69. It was found that higher yields were obtained 
when reaction time was kept as short as possible, and when better leaving groups 
where employed. The leaving group has a decisive influence on the stereochemistry o f 
the 1,3-substitution in propargylic systems69. It is possible for the reaction mechanism 
to change with different leaving groups. Studies showed that the best leaving groups 
were either the methyl- or toluene-sulphonate esters, which reacted in the anti mode at 
all temperatures69.
Jackson’s group investigated the reaction of the zinc reagent (31) under both 
palladium and copper catalysed conditions with tosylated 3-butyn-2-ol (41) to give 










We decided to carry out this reaction running the palladium and the copper 
catalysed reactions side by side as (41) is similar to the terminus of the propargylic 
substrate that we would use in our coupling reaction, and it would be a good 
indication of whether or not we were carrying out this methodology correctly. 
Racemic 3-butyn-2-ol (40) was tosylated in dry pyridine, the product was isolated in 
excellent yield, and then purified by crystallisation from ethanol.
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A suspension of zinc in dry THF was activated with 1,2-dibromoethane and TMS- 
chloride. The suspension was then treated with a solution of the iodide (36) in THF, 
followed by a solution of (41) and tetrakis(triphenylphosphine)palladium in THF. After 
work-up no allenic product could be detected, although the starting material (36) was 
destroyed.
The copper catalysed reaction involving the in situ formation of the zinc* / 
copper couple (39) fared much better. The zinc organometallic was prepared in the 
same way as for the palladium catalysed reaction, and then treated with a solution of 
copper cyanide and two equivalents o f lithium chloride in THF. The solution was then 
cooled and treated with the tosylated 3-butyn-2-ol (41). Work-up gave the allenic 
product (42) as a colourless oil in very good yield. The presence of the allene was 
confirmed by infra-red and N.M.R. spectroscopy.
Now that we had an established method for the coupling of an alanine p-anion 
equivalent to an acetylene, we needed to construct the amino acid / acetylene 
substrate itself. The substrate needs to be of the type shown in figure 9 with the leaving 






It was decided that this could be most effectively synthesised by the 
nucleophilic addition of a propargylic anion to the aldehyde (43), aspartic acid p- 
semialdehyde, as shown in scheme 27. The hydroxyl group could then be converted 
into a good leaving group, for example a tosylate.
The aldehyde (43) had already been synthesised at Zeneca Agrochemicals where it was 
an intermediate in the study of DHDP synthase73. At the company the initial strategy 
was the oxidation of protected DL-homoserine to the aldehyde. However, it was found 
~ that homoserine readily cyclised under the reaction conditions for amino-protection 
and that yields were very low due to the formation of the lactone, scheme 28.





Eventually the company abandoned this method and used a new route starting from 
allylglycine (44) instead, scheme 29. The starting material was protected in two steps 
to give N-t-butoxycarbonyl DL-allylglycine benzyl ester (46).
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We decided to work out the initial strategy using the cheaper racemic starting 
material, which could be replaced with chiral allylglycine to give enantiomerically pure 
product once the methodology had been worked out.
NH3 „  NH-T PhSOj ^  „
PhSO^H | 3 3 (B o c^O
C° 2* ! S ! ,  C 0 2 CH2Phakohol
(44) (45)
NHC02  t-Bu 1 . 0 3 , CH2 Cl2 »-78°C NHCOz t-Bu
O H C .^
(43)
C 0 2CH2Ph 2 .B 3N ( 2 e q ) ,- 7 8 C - 0 C  XOjCHjPh
(46)
Scheme 29
The doubly protected allylic compound was then subjected to ozonolysis74,75 at 
-78 °C in DCM to give the required aldehyde (43) in 50% yield. With the aldehyde 
available nucleophilic addition with an acetylene unit to give the propargylic amino 
acid needed to be attempted, scheme 30.
NHCO} t-B u OH N H C O , t-B u
Scheme 30
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It is worth noting that during this reaction another chiral centre is created. It 
should be possible to separate the diastereomers and investigate the difference in 








The reaction of Grignard and organolithium reagents with carbonyl compounds 
~ to yield alcohols is one of the most fundamental and versatile reactions in organic 
chemistry and has wide-spread synthetic applications. After consultation with 
colleagues at Zeneca, who had experience with reactions related to ours, it was 
decided to attempt the coupling reaction with lithium TMS-acetylide. Ethynyltrimethyl 
silane was treated with butyllithium at -78°C in THF, under nitrogen atmosphere, after 
stirring for an hour the lithiated compound was added dropwise to a solution of 
aldehyde (43) in THF, also at -78°C under nitrogen. Despite several attempts at this 
reaction no product was detected and only benzyl alcohol was obtained in the pure 
state. In addition a gummy material was also formed during the reaction but this 
proved extremely intractable and its Lr. spectrum revealed no discernible functional 
groups.
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A possible problem in this attempt is that the free hydroxyl group formed in the 
reaction is deprotonated under the basic conditions and caused lactonisation as shown 
in scheme 31. If this is the case, however, the lactone must undergo further reaction 
since neither it or any derivatives were isolated.
It was hoped that this problem might be overcome by replacing the relatively labile 
benzyl protecting group with a *Bu unit, scheme 32. Boc protection was carried out by 
bubbling 2-methylpropene gas through a stirred solution of (±)-allylglycine in DCM in 
the presence of sulphuric acid at sub-zero temperatures. The tert-butyl ester 
hydrochloride (47) was isolated as a clean white solid in good yield.












The reaction with the acetylide was carried out again using the Boc/Bu-ester 
protected aldehyde (49) using the same conditions but again none of the desired 
product was isolated. Only an intractable gum was produced. In another attempt a 
solution of (49) in THF was treated with an equivalent o f lithium (TMS)acetylide (50). 
Once more this M ed, as did a similar reaction with (trimethylsilyl)ethynyl magnesium 
bromide (51). The coupling was also attempted using stabilised lithium acetylide (52) 
but with the same result.
Me^ Me^
— ■“ — Li — — MgBr H—  Li
Another reason for the M ure might be that the basic conditions effected 
a-deprotonation of the aldehyde causing aldolisation and hence the inextractable gum. 
To avoid this we decided to synthesise the epoxide (54) from the doubly protected 
M allyl glycine and to attack this compound with lithium acetylide.
Two reagents were individually used to form the epoxide, m-CPBA76 and 
dimethyldioxirane (DMDO) 77-*2 (53). The DMDO method was attempted first. This 
reagent is formed by the reaction between acetone and potassium monoperoxy 
-sulphonate (caroate), as shown in scheme 33. The yield of DMDO is very low 
(around 5%), but the advantage is that the only side product of the epoxidation is 
acetone, making it easy to purify the product, and in our hands the yield of epoxide 
(54) was high (84%). The epoxidation was also attempted using m-CPBA and, 
although there was no problem with the BOC-protecting groups, the crude product 
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(53)
Scheme 33
u r  n  NHCO 2 t-Bu NHC02  t-Bu




The epoxide was then treated with lithium acetylide in the anticipation that it 
would afford the alcohol (55), scheme 35. Unfortunately this did not occur, but none 
o f the intractable gum was produced.
NHC02 t-Bu H OH NHCO 2 t-Bu
^  j T  X C02 t-Bu
(54) (55)
Scheme 35
This result substantiated our view that the earlier failures were largely due to 
enolisation of the aldehyde and other attempts were made to overcome this problem. 
One method for avoiding strongly acidic or basic conditions is the generation of 
acetylides from trimethylsilylacetylenes using a catalytic amount of 
tetrabutylammonium fluoride, scheme 36 83.
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The acetylides produced are less reactive than the corresponding lithium 
species and have been reported to react well with carbonyl compounds to give hydroxy 
acetylenes in good yields. This fluoride catalysed addition of silylacetylenes to carbonyl 
compounds was attempted using TMS-acetylene and bis(TMS)acetylene, but the lower 
basicity of the reagent had little affect and frustratingly a gum formed.
Bu.NF r ©  “I
R ■■■ SMe3 — — ► R— © Bu4N
(R= H or SiMe^ )
Scheme 36
An alternative and one o f the best ways o f avoiding unwanted side reactions in 
carbonyl addition reactions is the use of lanthanides84-89. Lanthanide reagents are 
becoming increasingly important in organic synthesis and many of their applications 
_ deal with trivalent lanthanides which are the most common.
Anhydrous cerium chloride is most often the reagent of choice as it is readily 
obtained by the dehydration of its heptahydrate, it is relatively inexpensive, and shows 
low toxicity. It has been observed that organocerium (III) reagents, generated by the in 
situ transmetallation from organolithium or Grignard reagents, undergo efficient 1,2- 
addition to carbonyl groups with remarkable suppression of abnormal reactions such as 
enolisation, aldol condensation, reduction, and conjugate addition in the case of a,p~ 
unsaturated substrates84-89. These characteristic reactivities of organocerium reagents 
are mainly ascribed to attenuated basicity and high oxophilicity. Trivalent cerium 
shows a strong affinity for oxygen atoms and is capable of activating carbonyl groups 
by co-ordination.
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This activation may be the most important driving force for cerium chloride 
promoted carbonyl additions, the other important factor being the low basicity of 
organocerium reagents compared to their organolithium and Grignard counterparts.
Little is known of the structure of these organoceriums, or the exact nature of 
the reactive species. Although they have been denoted as trivalent a-bonded species 
(“RCeCL”), other compositions (e.g. RM-CeCk, “ate” complexes) cannot be ruled 
out84. Regardless of the true nature of the reactive nucleophiles, they react efficiently 
with aldehydes and ketones, providing alcohols in yields that are often superior to 
those reported utilising organolithium or Grignard reagents84-89. In feet, some reactions 
not involving cerium chloride afforded no trace of addition products, while those 
utilising organo cerium compounds showed yields as high as 95% 84’86. It was thus 
decided to form the cerium (III) chloride derivative of lithium acetylide and use this in 
the coupling reaction with aldehyde (49), scheme 37.
CeCL




Cerium (HI) chloride was finely ground and heated in vacuo to around 140°C 
for two hours and protected by a nitrogen atmosphere. The solid was then cooled in an 
ice bath and dry THF was then added via a syringe and the flask placed in an ultrasonic 
bath at room temperature for 1 hour.
The resulting white slurry was cooled to -78°C and a solution of an ethylene 
diamine complex of lithium acetylide in dry THF was added dropwise. After stirring at 
-78°C for one hour a solution of aldehyde (49) in dry THF was added and the reaction 
mixture stirred for three hours, maintaining the low temperature. After work-up and 
several attempts at this reaction starting material was recovered unchanged. It is most 
likely that since cerium also shows a high affinity for nitrogen that it is binding to the 
ethylene diamine stabilising agent, possibly causing the degradation of the lithium 
acetylide in the process, and so preventing reaction. Sodium acetylide was then used, 
which requires no stabilising agent, but only a resinous gum was obtained from the 
reaction mixture, suggesting that transmetallation with the cerium chloride was not 
taking place, while enolisation was. We also tried the reaction with lithium 
(trimethylsilyl)acetylide but none of the desired product could be isolated.
We then carried out the reaction using lithium phenylacetylide in place of 
lithium acetylide, which has no stabilising reagent, to make sure that it was not the 
preparation of the cerium suspension which was the problem, (scheme 38). The same 
reaction conditions were used as above and the product (57) was isolated in excellent 
yield, thus showing that the coupling reaction was being carried out correctly and that 







These disappointing results prompted us to attempt the coupling using yet 
another method. We have already seen, in the cases o f the palladium and copper 
catalysed reactions, that transition metals mediate the formation of carbon-carbon a- 
bonds under much milder conditions than the simple lithium and Grignard 
organometallics. Organocopper reagents in particular have become popular among 
organic chemists. The widespread acceptance and use of organocopper reagents is 
largely attributable to their ease of preparation and their ability to effect 
transformations difficult or impossible to accomplish with other reagents90'96. 
However, while there is substantial literature on the addition of copper reagents to 
propargylic species90*96, there is none on the transfer of acetylenes from copper. The 
effectiveness of copper-acetylene reagents is yet to be seen.
Organocopper complexes are intrinsically correlated with such major pathways 
for carbon-carbon bond formation as nucleophilic displacements of halides, 
sulphonates, and allylic acetates, epoxide ring openings, additions to acetylenes, and 
conjugate additions to a,p-unsaturated carbonyl compounds90*92,96. It has been shown 
that for conjugate additions there is competition between 1,2-addition and 1,4- 
addition. Some organocuprates favour one route over the other, and in the cases of 
non- a , p-unsaturated carbonyl compounds, organocuprates do undergo efficient 
1 ,2 -addition95.
Mono-organocopper compounds (RCu), prepared from organic halides and 
activated copper metal, are thermally very unstable and decompose readily at 
temperatures above -15°C 90*92.
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Polynuclear structures have been suggested for most of these types of 
compound, which tends to make them insoluble in conventional organic solvents90. 
They are also considerably less reactive than the corresponding lower order cuprate 
species (R2CuLi / RaCuMgX), often referred to as “Gilman” type reagents90'96. These 
homocuprate reagents are the most widely used of the organocopper reagents, 
showing much greater reactivity than the mono-organocopper compounds. These 
lower order organocuprates are usually prepared by a transmetallation reaction 
between the corresponding organolithium or Grignard reagents and a copper (I) salt. 
The preparation is easy and the reactions of the resulting reagents are usually 
characterised by high chemo-, regio-, and stereoselectivity. However, one of the major 
limitations of most lower order cuprates concerns their thermal stability. While more 
stable than the mono-organic species they still show a tendency to breakdown90,92’96.
The stability of these reagents can be greatly improved by the formation of 
lower order heterocuprates (RCu(Z)Li), where enhanced thermal stability is imparted 
by the presence of a donor molecule, usually a cyano-group, which is incorporated into 
the molecule itself90"96. These lower order heterocuprates are formed using copper 
cyanide which is the best precursor97, whereas copper (I) halides often undergo 
incomplete cuprate formation, leaving free organolithium reagents in solution, 
something we desperately want to avoid. CuCN is also inexpensive, nonhygroscopic 
and light insensitive. Another advantage is that only one equivalent of a potentially 
valuable organolithium is required for the formation of an active reagent92'95,97.
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These mixed ligand lower order cyanocuprates, however, have the 
disadvantage of being considerably less reactive than the diorgano-homocuprates, or 
Gilman reagents, prompting chemists to investigate the synthetic potential of higher 
order, mixed ligand cyanocuprate reagents92"95. Higher order cyanocuprates, 
stoichiometrically represented as “R2Cu(CN)Li2”, are distinctly different from the 
Gilman reagents by virtue of two distinguishing features:
1. They are believed to be copper (I) dianionic species, implying that three ligands are 
bound to the copper (I) centre.
2. They contain a cyano-group, which presumably imparts the required rc-acidity to the 
lower order cyanocuprate, RCu(CN)Li, so that another equivalent of an 
organolithium can be accepted.
It was originally believed that higher order cuprates of the form “R3CuLi2” also 
~ existed but research has shown that addition of three molar equivalents of an 
organolithium to a copper (I) halide affords only R2CuLi and free RLi, rather 
than“R3CuLi2” 90’93'95. The term higher order cuprates has therefore now come to imply 
the mixed ligand cyanocuprates. These higher order heterocuprates have proved to be 
extremely versatile synthetic reagents. They are formed easily, and combine the 
increased stability of lower order heterocuprates with the reactivity of the Gilman type 
reagents. In feet, in some cases higher order cyanocuprates show greater reactivity 
relative to that of the Gilman type reagents, perhaps because of the build-up of 
negative charge in the cluster (i.e. as dianions rather than as monoanions)90,93*95. It was 
due to this increased stability yet high reactivity that we opted for higher order 
cyanocuprates in our research
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Higher order cyanocuprates containing only one transferable ligand have also 
been generated by incorporating a second dummy ligand in addition to the cyano-
ligand, including acetylenes themselves which was rather worrying. The ligand of 
choice though, is the thiophene group (58), shown in scheme 39 90,93’95,98. Thiophene 
(Th) itself is very cheap, and is essentially quantitatively metallated with strong base. 
Treatment with CuCN then forms the homogeneous, stable lower cuprate 
(2-Th)Cu(CN)Li (59).
Subsequent introduction of the lithiated transferable ligand (RrLi) immediately 
forms the higher order species, Rr(2 -Th)Cu(CN)Li2, which selectively releases the Rt 
group90’93'95’98. The stable lower order thienyl-cyanocuprate is commercially available, 
allowing chemists to bypass the handling of the copper (I) salt.
As previously mentioned, one of the distinguishing features between lower 
order and higher order cuprates is the mono- vs. dianionic lithium cations. It has been 
shown that the use of mixed metal reagents does not compromise the reactivity o f the 
higher order reagent, so cuprates of the form RTRRCu(CN)LiMgBr or 
RrRRCu(CN)LiNa may also be used, thus enabling the use of Grignard or sodium 
metallated reagents in the formation of the higher order cuprate95.






With this in mind we proposed to attempt the acetylene coupling using the 
mixed ligand, mixed metal higher order cyanocuprate (60), formed by the treatment of 
the lower order thienyl-cyanocuprate (59) with sodium acetylide, scheme 40.
u(CN)Li + H i Na ■    u(CNX > 1 H)LiNa
(59> (60)
OH NHCO, t-Bui I -*>
'C 0 2 t-Bu
(56)
Scheme 40
A 0.25 molar solution of lithium-2-thienyl cyanocuprate (59) in THF, 
purchased from Aldrich, was treated with an 11% suspension of sodium acetylide in 
xylene, at -78°C under nitrogen atmosphere. After stirring the solution at -78°C for half 
an hour a solution of aldehyde (49) in THF was added and the reaction mixture stirred 
for two hours maintaining the low temperature. After work-up we discovered that the 
higher order cuprate formed during the reaction had selectively transferred its 
“non-transferrable” ligand forming (61), which was the sole isolated product. No 
product resulting from enolisation was detected, so we were certain that no free 
sodium acetylide was present in solution and the higher order derivative did form. We 





It was then decided to form another higher order cyanocuprate with a different 
residual ligand, and we opted for the methyl group which has been used with great 
success for such a purpose. We attempted the formation of this reagent by a 
transmetallation reaction between the higher order dimethyl species (64), formed by 
the reaction of two molar equivalents of methyl lithium, copper cyanide and 
tributyl(ethynyl)tin (63), scheme 41. This method of forming the higher order reagent 
with the correct Rj has been used for a number of alkenyl species and is was hoped 
that it would prove equally successful for transferring acetylenes93,99.
H      SnBu3
(63)





Copper cyanide in THF was treated with two equivalents of methyl lithium at -78°C 
under nitrogen, and the solution stirred for half an hour. The reaction mixture was 
allowed to warm to room temperature and then treated dropwise with tributyl(ethynyl) 
tin and stirred for one hour.
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A colour change from colourless to a deep red was observed, pointing to 
formation of the acetylenic cuprate. The reaction mixture was cooled back down to - 
78°C and treated with a solution of aldehyde (49) in THF, then stirred for three hours, 
monitoring the reaction by tic. Work-up and isolation o f product showed that the 
reaction had not gone as expected and we speculate that methyl transfer had taken 
place to give (6 6 ), however the N.M.R. was ambiguous.
~ group is bound too tightly to the metal centre. It is the strength of this attachment that 
led us to abandon the use of copper altogether.
OH NHC02 t-Bu
(66)
In several cases in the literature acetylenes are used as the non-transferable 
ligands in mixed ligand cuprate chemistry93-95,10®*102, and we assumed that the alkyne
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M ethod 4 - Alleges via terminal conjugated enynes :
Another important way of making allenes, and an alternative to the 1,3-substitution of 
acetylenes, is 1,4-addition to enynes103"105. Terminal conjugated enynes are important 
intermediates for the synthesis of naturally occurring allenes and have been utilised 
successfully in laboratory syntheses103"105. Consequently, we proposed to synthesise 
the terminal enyne (67) as an alternative to the activated derivative of acetylene (56).
NHC02  t-Bu 
C 0 2CH2Ph
(67)
There are a number of methods for the preparation o f terminal enynes but due to the 
shortage of time only a handful were looked into. It was decided initially to attempt an 
~ Emmons-Homer reaction which is often the preferred method. An example where this 
works well is the synthesis of 4-phenyl-3-buten-l-yne105.
O 
II
Br P—(OEt)2 i Base
IMS— ------- f  -------► TMS— = --- '   ► Ph
ii Benzaldehyde
Whereas this method offers the advantages of increased stability o f the phosphonate 
carbanion and water soluble phosphate by-products, it could not be used in the 
synthesis o f enyne (67) as this would involve the aldehyde (6 8 ), (scheme 42), which 
seems to be unstable, as all previous attempts at its synthesis have foiled.
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y  NHC02 t-Bu NHC02 t-Bu
P^OEfc +  h  Jl  ^




It was therefore decided to switch strategy and make the ylide of the amino acid 
component (69) and couple this with propynal (70), Scheme 43. The iodide (36) was 
made as earlier in scheme 2 2  where it was used in the synthesis of the alanine p-anion 
equivalent. It was then treated with triethylphosphite in THF and refluxed overnight. 
Work up gave the required phosphonate (69) as a white powder in excellent yield.
NHC02 t-Bu O NHC02 t-Bu
j T ii i
%s ^^SfcC02CH2Ph (EtO)2^  \ ^ X 0 2CH2Ph
(36) , (69)





Propynal (70) was synthesised by the Jones oxidation of propynol108. Unfortunately, 
the product was contaminated with ethyl methyl ketone, which is recommended as a 
co-solvent. The presence of this ketone was a nuisance and when a coupling reaction 
was attempted on the crude product we failed to detect the presence of the required 
compound (67) in the reaction mixture.
We also tried to find an alternative solvent for the preparation of the aldehyde (70) and 
we carried out preparative reactions using (a) nitrobenzene and (b) dimethyl 




At this point laboratory work had to stop and yet the target compounds had 
eluded us. Much time has been used up following approaches to them which in our 
hands reached dead ends. However, the Emmons-Homer synthesis, despite the initial 
disappointment, still seems to have promise and work remains to be done on finding a 
suitable solvent which will allow the preparation of propynal (70) in good yield.
Another route to terminal enynes is that involving the Songashira Cu-Pd 
catalysed alkyne coupling reaction109. Under these conditions a terminal alkyne can be 
coupled with a vinyl halide as shown in scheme 44, although the synthesis of a suitable 
vinyl halide substrate would have to be looked into.
Alternatively, propynal could be coupled with iodide (36) under chromium (II)
could then be activated and treated with Jackson’s organozinc reagent (31), scheme 
45, or both the amino acid components could be added under copper catalysed 
conditions with the organozinc reagent (31), scheme 46.
Cu(I), Pd(II), Base
Scheme 44
conditions110,111 to give the hydroxy-acetylene compound (56) discussed earlier, which
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9 ( OH NHCO,
Scheme 46
Finally, if none of the above routes proved productive, it is felt that it would be 
worthwhile going back to the palladium catalysed alkylation discussed in the first 
earlier and shown in scheme 17. Although the reaction was low yielding it was still 
successful and could be carried out on a large enough scale to produce sufficient 





Petroleum ether (petrol) refers to petroleum spirit, b.p. range 60-80°C, and 
ether refers to diethyl ether. Reaction solvents were dried and distilled before use, as 
were solvents used for chromatography. Tetrahydrofuran (THF) was pre-dried over 
sodium wire, and then refluxed over sodium benzophenone ketyl until dry, and 
re-distilled prior to use. DCM and triethylamine (NEt3> were dried by distillation from 
calcium hydride, and methanol (MeOH) and ethanol (EtOH) were distilled from 
magnesium turnings.
For reactions performed under dry nitrogen, the glassware and apparatus were 
dried overnight in an oven at 125°C, then allowed to cool in a dessicator. Flasks were 
sealed with rubber septa and flame dried before use. All reactants were transferred 
with syringes and needles.
All yields quoted are of purified products, unless otherwise stated.
Specroscopv
N.m.r. spectra were recorded at 270 Mhz (!H), and were run in 
deuteriochloroform (CDCI3) with trimethyl silane (TMS) as the internal standard, 
unless otherwise stated. Chemical shifts (8 ) are expressed as downfield shifts from 
TMS with multiplicities denoted by s (singlet), d (doublet), t (triplet), q (quartet), p 
(quintet), dd (doublet o f doublets), dt (doublet of triplets), bs (broad singlet), m 
(multiplet), and bm (broad multiplet).Infrared (i.r.) spectra were recorded as liquid film 
or nujol mulls, with the absorption frequencies (o) expressed in cm'1. Mass spectra 
(m.s.) were recorded using electron impact (E.I.) and/or chemical ionisation (C.I.) 
techniques, quoting the molecular ion (M)+ and/or protonated molecular ion (M +l)+ 
respectively. In addition, the base peak and sizeable fragments are denoted with 
assignments, where possible. Elemental microanalyses were obtained from the Physical 
and Chemical Measurement Unit (University of Bath).
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Dimethyl 3-chloropent-2-ene-l,5-dioatesl (11).- Phosphorus pentachloride (108 g,
520 mmol) was added portionwise to diethyl pentan-3-one-l,5-dioate (95.9g,
474 mmol) under an atmosphere of nitrogen with stirring. After addition was 
complete, the reaction mixture was warmed to 40°C for 30 min, during which time a 
red colouration developed. The reaction mixture was then cooled in an ice bath and 
poured onto ice (200 cm3) in an ice-cooled flask. A mixture of water and DCM 
( 1 : 1  v/v, 1 0 0 cm3) was used to wash traces of product from the reaction vessel, and the 
resulting mixture was stirred for 15 min. After separating the two layers, the aqueous 
phase was extracted with DCM (3 x 80 cm3) and the combined organic extracts dried 
(Na2SC>4) and concentrated under reduced pressure to yield a red oil. This was added 
to a mixture of concentrated sulphuric acid (26 cm3) and dry methanol (350 cm3) and 
heated under reflux for 18 h. Excess methanol (250 cm3) was removed by distillation, 
the residue allowed to cool to RT and then poured into water (150 cm3). Sodium 
chloride was added to saturation and the solution extracted with ether ( 6  x 1 0 0  cm3). 
The combined ether extracts were washed successively with saturated aqueous 
NaHCC>3 solution ( 1 2 0  cm3) and saturated aqueous NaCl solution ( 1 2 0  cm3), dried 
(MgSC>4) and concentrated under reduced pressure to afford a yellow oil. Purification 
was effected by distillation under reduced pressure to afford the title compound (1 1 ) 
(46.3 g, 51%) as a colourless liquid, b.p. 70-80°C at 0.1 mmHg, (lit. , 115 b.p. 50-60°C at 
0.02 mmHg). The product was determined to be a mixture of stereoisomers 
(approximately 6:1) by *H n.m.r. The spectral data of (5) were in accord with 
published data;115 i w  (liquid film) 3080 (HC=), 2955, 1719 (CO-O), 1640 (HC=), 
1430 cm 1; 5h (CDC13) 3.73 (3H, s, CH3O-COCH2), 3.75 (3H, s, C^HCO-OCHb), 
4.12 (2H, s, CH3O-COCH2), 6.21, 6.28 ( 1 H, 2  x s, stereoisomeric C=CH);
8 c (CDCI3), 41.2 (C=CHCH2), 51.6 (CH3O-COCH2), 52.3 (C=CHCO-OCH3),
121.5 (C1C=CH), 150.0 (C1C=CH), 164.4 (CH30-C0CH2), 168.1 (C=CHCO-OCH3); 
m/z (C.I.) 193 (M+l)+ (19%), 161 (M-CH30 )+ (100%).
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Dimethylpent-2,3-dienedioatesl (12). - To a stirred solution of (11) (45.0 g, 233 
mmol) in dry THF (150 cm3) at 0°C under a nitrogen atmosphere was added freshly 
distilled triethylamine (39 cm3, 280 mmol) portionwise over a 10 min period. The 
nitrogen inlet/outlet was then replaced by a drying tube (CaCk) and the mixture stirred 
for 18 h at 0-5°C. During this time a precipitate o f triethylamine hydrochloride formed 
which was removed by filtration and washed with ether (3 x 25 cm3). The combined 
filtrate and washings were washed successively with 0.1 N hydrochloric acid 
(3 x 20 cm3) and saturated aqueous NaCl solution (25 cm3). After drying (Na2SC>4) the 
ethereal solution was concentrated under reduced pressure to yield a red / orange oil 
The oil was purified by distillation under reduced pressure to afford the title compound 
(12) (22.1 g, 60%) as a colourless liquid, b.p. 78-80°C at 0.1 mmHg (lit. , 115 58°C at 
0.02 mmHg). The product became yellow and viscous on standing at RT, due to 
polymerisation, and was thus stored at -20°C. The spectral data of (12) were in 
accordance with published data;115 Umax (liquid film) 2960,1960 (C=C=C),
1710 (CO-O) cm 1; 8 h (CDC13) 3.78 (6 H, s, 2 x CH30-CO), 6.07 (2H, s, HC=C=CH); 
6 c (CDCI3) 52.3 (2 x CH3O-CO), 91.9 (C=C=Q, 163.5 (CH3O-CO), 219.5 (C=C=C); 
m/z (E l.) no (M)+, 125 (M-CH30 )+ (77%), 6 6  (34), 59 (100), (C.I.) 157 (M +l)+ 
(100%), 125 (64%).
1
l,5-Dihydroxypent-2,3-diene (9).- A 1.5 M solution of Dibal-H in toluene (70 cm3,
102.4 mmol) was added portionwise over 1 h to a stirred solution of dimethyl 
penta-2,3-dienedioate (12) (4.00 g, 25.6 mmol) in dry toluene (100 cm3) at 0°C under 
nitrogen. After 1.5 h of additional stirring at 0-5°C, a saturated solution of sodium 
potassium tartrate (95 cm3) was slowly added to the cooled reaction mixture which 
was then allowed to warm to RT. The toluene was separated off and the aqueous 
portion extracted by continuous extraction into ether over two consecutive 15 h 
periods. The combined organic isolates were dried (Na2SC>4), and then evaporated 
under reduced pressure to afford an orange oil. Purification of the crude product by 
column chromatography [silica gel, petrol-EtOAc (9:1)] gave the title compound (9) 
(1.23 g, 48%) as a colourless oil.
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The product was stored at -20°C as polymerisation occured on standing at RT; 
i w  (liquid film) 3600-3100 (OH), 2920,2860, 1969 (C=C=C) cm 1; 8 h (CDC13)
2.39 (2H, bs, OH), 4.16 (4H, t, J=4.2 Hz, 2 x CH2OH), 5.51 (2H, t, J=4.2 Hz, 
HC=C=CH); 8 c (CDCI3) 60.1 (2 x CH2OH), 94.7 (C=C=Q, 202.5 (C=C=C); 
m/z (E.I.) no (M)+\  82 (M-H20 )+ (99%), 55 (100), (C.I.) 101 (M + lf (8 ), 100 (69),
83 (M+1-H20 /  (100%), 56 (26%).
Pent-2,3-diene-l,5-dimesylate (13).- Freshly distilled triethylamine (240 mg,
2.2 mmol) was added dropwise to a stirred solution o f l,5-dihydroxy-penta-2,3:diene 
(9) (100 mg, 1.0 mmol) and methanesulphonyl chloride (270 mg, 2.2 mmol) in dry 
DCM (5 cm3) at 0°C under nitrogen. The reaction mixture was stirred for 2 h at 0-5°C. 
During this time a precipitate of triethylamine hydrochloride formed which was 
removed by filtration and washed with DCM (3x10 cm3). The reaction mixture was 
then poured onto ice cold 2 N Hydrochloric acid / ice (1:2 v/v 10 cm3) and the organic 
layer separated. The aqueous layer was then further extracted with DCM (2 x 20 cm3), 
and the DCM isolates combined, dried (Na2SC>4), and concentrated under reduced 
pressure to afford the mesylate (13). The crude product was then dissolved in dry 
toluene ( 2 0  cm3) and filtered to remove any remaining triethylamine hydrochloride 
salts. The toluene was then removed under reduced pressure to afford the title 
compound as a yellow oil (128 mg, 50%). Storage at -20°C was employed to prevent 
decomposition. The compound was to be used without further purification as 
decomposition occured during column chromatography; Umax (liquid film) 2957,2872, 
1972 (C=C=C), 1352 and 1173 (S020); 8 h (CDC13) 2.97 (6 H, s, 2 x CH3S020),
4.71 (4H, dd, J=3.9,1.5 Hz, 2 x S020CH2), 5.42 (2H, m, HC=C=CH); 5C (CDC13) 
37.7 (2 x CH30 S 0 2), 66.4 (2 x S020CH2), 88.9 (HC=C=CH), 207.3 (HC=C=CH); 
no m/z due to decomposition.
Pent-2,3-diene-l,5-bis-(ethyl-N-(diphenylmethylene)glycinate) - A solution of (18) 
(191mg, l.Ommol) in dry THF (3 cm3) was added to a solution of potassium tert- 
butoxide (113mg, l.Ommol) in dry THF (5 cm3) at -78°C under nitrogen atmosphere, 
followed by a solution of (13) (130mg, l.Ommol) in THF (5 cm3).
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The solution was allowed to warm to room temperature and stirred for a further 2 
hours, following the reaction by thin layer chromatography. Work-up involved 
extraction of the crude product into diethyl ether ( 2  x 2 0  cm3) and washing of the 
combined organic extracts with saturated aqueous ammonium chloride solution 
(4x10 cm3). The organic layer was then dried (Na2SC>4), filtered and concentrated 
under reduced pressure to give an orange oil (108 mg). None o f the data acquired on 
the crude compound corresponded with the desired product.
5-(t-Butyldiphenylsilyloxy)pent-2,3-diene-1 -ol (14).- To a stirred solution of
l,5-dihydroxypenta-2,3-diene (9) (174 mg, 1.7 mmol) in dry DCM (10 cm3) containing 
imidazole (118 mg, 1.7 mmol) under nitrogen atmosphere was added 
/-butyldiphenylsilyl chloride (479 mg, 1.7 mmol) dropwise at RT. After 2 h the 
reaction mixture was filtered through a celite pad and evaporated under reduced 
pressure to afford the crude silyl ether which was purified by column chromatography 
[silica gel, petrol-EtOAc (4:1)] to yield the title compound (14) (180 mg, 32%) as a 
colourless oil; Umax (liquid film) 3600-3100 (OH), 3070,3049 (Ar-H), 2935,2857,
1966 (C=C=C), 1100 and 820 (SiOC) cm'1; 8 h (CDC13) 1.05 (9H, s, C(CH3)3), 1.54 
“ (1H, bs, OH), 4.08 (2H, dd, J= 8 .6 , 3.2 Hz, HOCH2), 4.25 (2H, dd, J= 8 .8 , 3.1 Hz, 
CH2OSi), 5.41 (2H, m, HC=C=CH), 7.35-7.73 (10H, m, H-aromatic); 6 C (CDC13)
19.3 (C(CH3)3), 26.9 (C(CH3)3), 60.5 (HOCH2), 61.9 (CH2OSi), 93.6 (HC=C=CH- 
CH2OSi), 94.4 (HOH2C-HC=C=CH), 127.7,129.7, 133.7,135.6 (C-aromatic) 205.8 
(C=C=C); m/z (FAB) 339 (M +l)+ (5%), 321 (M+1-H20 )+ (83%), 229 (58%), 199 
(100%), 143 (75%); [Found: C, 74.4; H, 7.9. C2 iH260 2Si requires C, 74.5; H,7.8%].
5-(t-Butyldiphenylsilyloxy)pent-2,3-diene-1 -mesylate (15).- Triethylamine (58 mg, 
0.53 mmol) was added dropwise to a stirred solution of (14) (180 mg, 0.53 mmol) 
and methanesulphonyl chloride (65 mg, 0.53 mmol) in dry DCM (5 cm3) at 0°C under 
nitrogen. After stirring for a further 2 h at 0-5°C the solution was poured into a 
mixture of 2 N hydrochloric acid and ice (2:1 v/v, 10 cm3).
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The organic layer was isolated and the aqueous layer extracted further with DCM 
(2x10 cm3). The combined organic layers were washed with saturated aqueous 
NaHCCb solution (2x10 cm3) and saturated NaCl solution (10 cm3), dried (Na2SC>4) 
and concentrated under reduced pressure to afford the mesylate (15). The crude 
product was then dissolved in dry toluene (20 cm3) and filtered to remove any 
remaining triethylamine hydrochloride salts. The toluene was then removed under 
reduced pressure to afford the title compound as a pale yellow oil (155 mg, 70%). 
Storage at -20°C was employed to prevent decomposition. The compound was to be 
used without further purification as decomposition occurred during column 
chromatography; Umax (liquid film) 3070,3049 (Ar-H), 2930,2856, 1968 (C=C=C), 
1361 and 1174 (S020), 1090 and 820 (SiOC) cm 1; 5h (CDC13) 1.06 (9H, s, C(CH3)3), 
2.93 (3H, s, CH3S020), 4.26 (2H, dd, J= 8.6,2.9 Hz, CH2OSi), 4.65 (2H, dd, J= 9.3,
2.0 Hz, S020CH2), 5.42 (2H, m, HC=C=CH), 7.37-7.69 (10H, m, H-aromatic); 6c 
(CDC13) 19.2 (C(CH3)3), 26.7 (C(CH3)3), 38.1 (CH30 S 0 2), 61.0 (CH2OSi), 67.8 
(S02OCH2), 87.6 (S02OCH2-CH=C=CH), 94.3 (HC=C=CH-CH2OSi), 127.6, 129.7,
133.3, 135.4 (C-aromatic), 205.7 (C=C=C); m/z (C.I., NH3) 434 (M+NH,)+ (98%), 
417 (M +l)+ (21%), 338 (M+1-S02CH3)+ (13%), 321 (M -0S02CH3)+ (52%), 143 
(74%).
Benzylidene glycine ethyl ester (17)60.- Benzaldehyde (3.79 g, 35.8 mmol) was added 
dropwise to a solution of glycine ethyl ester hydrochloride (5 .0 g, 35.8 mmol) and 
triethylamine (7.26 g, 71.8 mmol) and anhydrous magnesium sulphate (3 g) in dry 
DCM (75 cm3) at RT under nitrogen. The reaction mixture was stirred for 1 h. During 
this time a precipitate of triethylamine hydrochloride formed which was removed by 
filtration and washed with DCM (3x10 cm3). The combined filtrate and washings 
were washed with saturated NaCl solution (3 x 20 cm3) and saturated ammonium 
chloride solution (2 x 30 cm3). The organic layer was then dried (Na2SC>4) and 
concentrated under reduced pressure to yield the title compound (17) as a colourless 
oil (5.65 g, 63%). The compound was to be used without further purification as 
decomposition occured during column chromatography; Umax (liquid film) 1741 
(C02Et), 1647 (C=N) cm 1;
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5h (CDCI3) 1.3 (3H, t, J=7.1 Hz, C02CH2CH3), 4.2 (2H, q, J=7.1 Hz, C02CH2CH3),
4.4 (2H, s, NCHzCOz), 5.3 (1H, s, Ar-CH=N), 7.74 - 7.88 (5H, m, H-aromatics); 6C 
(CDCI3) 13.9 (C02CH2CH3), 60.8 (C02CH2CH3), 61.8 (N-CH2 C 02), 128.2,129.4, 
134.1, 135.4 (C-aromatic), 165.1 (Ar-CH-N), 169.8 (C02CH2CH3). m/z(C.I.) 192 
(M +l)+ (100%), 162 (M+l - C2H5)+ (25%), 118 (M+l - C02Et) (25%).
Ethyl N-(diphenylmethylene)glycinate (18).- Benzophenone inline (5.0g, 27.6 mmol) 
and an equimolar amount of finely ground glycine ethyl ester hydrochloride (3.85g,
27.6 mmol) were stirred in diy DCM (100cm3) in the presence of anhydrous 
magnesium sulphate (3g), at room temperature for 24 hours, with a calcium chloride 
drying tube. The reaction mixture was then filtered through a Celite pad to remove 
ammonium chloride and the solvent removed under reduced pressure. The residue was 
taken up in ether (100 cm3), filtered and washed with distilled water (100 cm3). The 
organic portion was then dried (MgS04), filtered and the solvent removed under 
reduced pressure. The solid was washed with a small amount of cold hexane and dried 
under high vacuum to yield a white crystalline solid (6.01g, 82%).; Umax (nujol mull) 
1964 (C=C=C), 1730 (C02Et), 1660 (C=N) cm 1; 8h (CDC13) 1.25 (3H, t, J=7.1 Hz, 
C 02CH2CH3), 4.2 (2H, q, J=7.3, 7.0 Hz, COzCILCHj), 4.2 (2H, s, NCHzCCh),
7.74 - 7.88 (10H, m, H-aromatics) ppm; 6C (CDC13) 14.1 (C02CH2CH3),
55.6 (C02CH2CH3), 60.7 (N-CH2 C02), 128.2, 129.4, 134.1, 135.4 (C-aromatic),
170.5 (Ar-C-Ar), 171.1 (C02CH2CH3) ppm; m/z (C.I.+) 268 (M+l)+ (90%),
194 (100%), 91 (90%).
5-(t-Butyldiphenylsilyloxy)penta-2,3-diene-1-diethylphosphate (20).- Freshly distilled 
pyridine (200mg, 2.53mmol) was added dropwise to a stirred solution of (14)
(306mg, 0.905 mmol) in dry DCM (5cm3) at 0°C, under nitrogen atmosphere, followed 
by diethyl chlorophosphate (218mg, 1.267 mmol). The reaction mixture was then 
allowed to warm to room temperature and stirred for 16 hours. The reaction mixture 
was then taken up in ether (25 cm3) and washed with 2N HC1 (30 cm3), saturated 
aqueous NaHCCb solution (30 cm3), and distilled water (30 cm3).
99
The organic portion was then dried (MgS0 4 ), filtered, and the solvent removed under 
reduced pressure to yield (20) as a colourless oil (333mg, 77%). Umax (liquid film) 1969 
(C=C=C), 1277 (P=0), 1050-1020 (P-0-CH2), 1090 and 820 (SiOC) cm 1; 8 h (CDC13)
1.04 (9H,s,t-Bu), 1.32 (6 H, t, J=7.0 Hz, 2 x C0 2CH2CH3), 4.10 (4H, p, J=7.15, 7.5 
Hz, 2 x C0 2CH2CH3), 4.26 (2H, dd, J=3.0, 8 . 6  Hz, CH2OSi), 4.48 (2H, ddd, J=2.6,
4.2 Hz, CH2OP), 5.40 (2H, m, HC=C=CH), 7.37-7.69 (10H, m, H-aromatic); 6 c 
(CDC13) 16.1 (OCH2CH3), 19.1 (C(CH3)3), 26.7 (C(CH3)3), 61.4 (CH2OSi), 63.7 
(OCH2CH3), 63.8 (CH2OP), 89.4 (HC=C=CH-CH2OP), 93.7 (HC=C=CH-CH2OSi),
127.6,129.6,133.4,135.5 (C-aromatic), 204.5 (C=C=C); m/z (F.A.B.) 475 (M +l)+ 
(32%), 417 (80%), 219 (80%), 135 (100%).
5-(t-Butyldiphenylsilyloxy)pent-2,3‘diene-l-ethyl-N-(diphenylmethylene)glycinate 
(21).- [note: all solvents were degassed] Diisopropylamine (33mg, 0.32 mmol) in dry 
THF (2 cm3) was treated with 2.5N n-BuLi in hexanes (0.130 cm3, 0.32 mmol) at 
-78°C, under nitrogen atmosphere, over a period of 5 minutes. (18) (79mg, 0.2947 
mmol) dissolved in dry THF (2 cm3) was added to the reaction mixture and the 
solution stirred at -78°C for 1 hour, and then allowed to warm to room temperature. A 
solution of Pd2(dba) 3 (1 lmg, 0.012 mmol) and triphenyl phosphine (19mg, 0.07 mmol) 
in dry THF (3 cm3) was added via a cannular, followed by the phosphate (20) (140mg, 
0.3 mmol). The reaction mixture was then stirred at room temperature for 5 hours.
The reaction mixture was then hydrolysed with saturated aqueous NH4CI solution (20 
cm3) and the product extracted with ether (3 x 30 cm3). The combined organic phases 
were washed with distilled water (2 x 25 cm3), dried (MgS0 4 ), filtered and the solvent 
removed under reduced pressure to yield a crude yellow oil (24mg). The product 
which was purified by column chromatography [silica gel, petrol-EtOAc (4:1)] to yield 
the title compound (21) (20mg, 16%) as a yellow oil; Umax (liquid film) 1964 (C=C=C), 
1730 (C02Et), 1660 (C=N), 1090 and 820 (SiOC) cm 1; 6 h (CDC13) 0.9 (3H, t, J=7.33 
Hz, C0 2CH2CH3), 1.0 (9H, s, t-Bu), 2.6 (2H, dt, HCOCH-CHz-CH), 4.15 (3H, m, 
OCHzCHa and HC=C=CH-CH2-CH), 4.33 (2H, t, J=6.65 Hz, CHzOSi), 5.05 (1H, m, 
HC=C=CH-CH2-CH), 5.15 (1H, m, HC=C=CH-CH2-OSi), 7.24 - 7.92 (20H, m, H- 
aromatics) ppm; 6 C (CDC13) 14.2 (C02CH2CH3), 19.1 (C(CH3)3), 26.7 (C(CH3)3),
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60.9 (CH2OSi), 62.4 (OCH2CH3), 65.4 (HC=C=CH-CH2-CH), 65.5 (HC=C=CH-CH2- 
CH), 88.3 (HC=C=CH-CH2-OSi), 91.5 (HC=C=CH-CH2-CH), ), 170.8 (Ar-C-Ar),
171.5 (C02CH2CH3), 204.2 (C=C=C) ppm; m/z (FAB) 563 (M +l)+ (3%), 489 
(100%), 323 (25%), 310 (10%).
Trans-1,4-bis [ethyl-N-(diphenylmethylene) glycinate)]-2-butene (23).- 
Diisopropylamine (1.04 g,10.3 mmol) in dry THF (5cm3) at -78°C, under nitrogen, was 
treated dropwise with 2.5N n-butyllithium in hexanes (4.1 cm3, 10.3 mmol) over a 
period of 10 minutes. A solution of ethyl-N-(diphenylmethylene)glycinate (18) (2.5 g,
9.35 mmol) in dry THF (5 cm3) was added to the solution in one go.
The resulting solution was stirred at -78°C for one hour. The solution was then 
allowed to warm to RT and stirred for a further 30 minutes before being cooled back 
to -78°C. A solution of trans-l,4-dibromo-2-butene (1.0 g, 4.67 mmol) and tetrakis 
(triphenylphosphine) palladium (0.30 g,0.256 mmol) in dry THF (5 cm3) was added 
and the reaction mixture allowed to warm to RT overnight. The resulting solution was 
hydrolysed with distilled water (30 cm3) and extracted with EtOAc (3 x 20 cm3). The 
« organic layers were combined, dried (Na2SC>4), filtered and concentrated under 
reduced pressure to afford the crude product as an orange oil, which was purified by 
column chromatography [silica gel, petrol-EtOAc (9:1)] to yield the title compound 
(23) as a yellow oil (1.47 g, 60%); Umax (liquid film) 1737 (CO-O), 1623 (C=N) cm'1;
Sh (CDC13) 1.20 (6H, t, J=7.32 Hz, 2 x OCHzCIT,), 2.55 (4H, m, 2 x CCH-CHz),
4.0 (2H, m, 2 x N-CH-C02Et), 4.10 (4H, q, J=7.3 Hz, 2 x OCHzCHa), 5.30 (2H, s, 
HC=CH), 12-1.6 (20H, m, H-aromatics) ppm; 6c (CDC13) 14.1 (2 x OCH2CH3),
36.8 (2 x C=CH-CH2), 60.7 (2 x OCH2CH3), 65.5 (2 x N-CH-C02Et), 127.7,127.9,
128.3, 128.5, 128.7, 128.9, 136.4, 139.5 (C-aromatics), 170.4 (2 x Ar-C-Ar),
171.7 (C02Et) ppm; m/z (F.A.B. accurate mass) 587 (M+l)+ (100%), 193 (30%).
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[6.1.0]-9,9-Dibromobicyclononane (27a).- A solution containing cyclooctene 
(0.5 cm3, 3.85 mmol) and bromoform (1.68 cm3, 19.23 mmol) in dry THF (10 cm3) 
stirred at -78°C, under nitrogen, was treated dropwise with 1.6M n-butyllithium 
(2.89 cm3, 4.62 mmol). The reaction mixture was stirred at -78°C for 30 minutes the 
treated with distilled water (20 cm3) and extracted with EtOAc (3 x 20 cm3). The 
organic portions were combined, dried (MgSOO, filtered, and concentrated under 
reduced pressure to afford the crude product which was dried under high vacuum to 
give the title compound (27) as an orange oil (650 mg, 60%). Umax (liquid film) 657 (C- 
Br) cm 1; 8h (CDC13) 0.99 (4H, t, J=7.33 Hz, C4Hz and C5Hz), 1.42 (4H, m, C3 Hz and 
C6Hz), 1.84 (4H, m, C^Hz and C7Hz), 2.95 (2H, m, C1 H and C8H) ppm; 6c (CDC13)
21.0 (C4 and C5), 25.3 (C3 and C6), 26.3 (C2) 27.8 (C7), 33.3 (C1 and C8), 35.0 (C9 
Br2) ppm.
[6.1.0]-9,9-Dibromobicyclononane (27b).- An aqueous 50% solution of sodium 
hydroxide (1.45 cm3, 18.18 mmol) was added dropwise to a vigorously stirred solution 
of cyclooctene (1.18 cm3, 9.09 mmol), bromoform (0.79 cm3, 9.09 mmol), and 
M benzyltriethylammonium chloride (lOmg), in DCM (10 cm3). The mixture was stirred 
for 3 hours at 40°C then allowed to cool to room temperature. A further 50 cm3 of 
DCM was added and the organic phase washed with water (3 x 50 cm3), dried 
(MgSC>4), filtered and concentrated under reduced pressure to give an orange oil which 
was dried under high vacuum to give the title compound (27) as an orange oil (1.07g, 
42%). 5h (CDC13) 1.02 (4H, t, J=7.32 Hz, C4Hz and C5Hz), 1.46 (4H, m, C^ Hz and C6 
Hz), 1.90 (4H, m, C2^  and C7Hz), 3.01 (2H, m, C1 H and C8H) ppm; 8C (CDC13) 21.2 
(C4 and C5), 25.3 (C3 and C6), 26.3 (C2) 28.0 (C7), 33.0 (C1 and C8), 35.1 (C9Br2) 
ppm.
1,2-Cyclononadiene (28) - A solution containing cyclooctene (1.0 cm3, 7.7 mmol) and 
carbon tetrabromide (2.5 g, 7.7 mmol) in diethyl ether (10 cm3), under nitrogen, was 
cooled to -60°C and then treated dropwise with 1.0M methyllithium 
(7.7 cm3, 7.7 mmol).
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After stirring at -60°C for half an hour another 1.1 equivalents of 1.0 M methyllithium 
was added dropwise, and after another 30 minutes the reaction was allowed to warm 
to 0°C. The organic layer was then washed with water (3 x 20 cm3), dried (MgSC>4), 
filtered, and concentrated under reduced pressure to give the crude title compound 
(28) as an ofi (535 mg, 57%). i w  (liquid film) 1960 (C=C=C) o n 1. 8h (CDC13)
1.4 - 2.4 (8H, m, CH2 for C4-C7), 1.65 (4H, m, CH2 for C3 and C8), 5.35 (2H, m, 
HC=C=CH) ppm. 6c (CDC13) 23.7 (C3 and C8), 26.3 (C4 and C7), 27.2 (C5 and Q>),
85.2 (HC=C=CH), 205.9 (HC=C=CH) ppm. B.p. Found 164-165°C.
(Literature64 = 167-169°C).
Bis-(trichloromethyl)mercury (29) - A solution of mercuric chloride 
(5.0 g, 18.4 mmol) and sodium tricloroacetate (6.8 g, 36.8 mmol) in
1,2-dimethoxyethane (30 cm3) was refluxed for 1 hour. The solution was allowed to 
cool to room temperature and then poured into water (200 cm3) and extracted with 
diethyl ether (3 x 100 cm3). The combined organic extracts were washed with fresh 
water (2 x 100 cm3), dried (MgS04), filtered and concentrated under reduced pressure 
m to give 5.6g of white solid which was crystallised from chloroform resulting in the title 
compound (29) as white prisms (2.5g, 31%). M.p. Found= 139°C.
(Literature68 = 140-141°C).
L-Serine benzylester benzenesulphonate (33) - A mixture of L-serine (21.02g, 0.2 
mol), 90% technical grade benzenesulphonic acid (45.0g, 0.25 mol) and benzyl alcohol 
(100 cm3) in carbon tetrachloride (250 cm3) was distilled using a Dean-Stark apparatus 
until no more water was collected (16 hours). The remaining solvent was removed 
under reduced pressure and diethyl ether (200 cm3) was added with vigorous stirring. 
The solution was stored in a freezer for 24 hours and the white solid which crystallised 
was filtered off and washed with fresh, cold diethyl ether. The product was dried under 
high vacuum to give the title compound (33) as a white solid (25.94g, 40%).
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8h (D20 ) 3.95 (2H, ddd, J=12.1, 4.2 Hz, CH2OH), 4.2 (1H, m, CHC02), (2H, s, 
CH2Ph), 7.4 -7.8 (10H, m, H-aromatics) ppm; 8C (D20 ) 54.9 (CHC02), 59.4 
(CH2OH), 68.8 (CH2Ph), 125.5,128.7,129.1, 129.2,131.8 (C-aromatics),
134.8 ((Ar)C-CH2C02), 142.5 ((Ar)C-S03), 168.4 (C02CH2) ppm. mp 96-97 °C 
(Lit.42 97-98 °C).
L-N-t-Butoxycarbonylserine benzylester (34) - Di-tert-butylpyrocarbonate (16.24g, 
74.41 mmol) was added to an ice cooled solution of (33) (25.0g, 74.41 mmol) ip dry 
THF (200 cm3) and 1M aqueous sodium hydroxide (75 cm3). The resulting solution 
was stirred at room temperature for 16 hours. The solution was then concentrated 
under reduced pressure, cooled in an ice bath and covered with ethyl acetate (100 cm3) 
and acidified with 10% w/v aqueous potassium hydrogen sulphate to pH 2-3. The two 
layers were separated and the aqueous washed with fresh ethyl acetate (2 x 100 cm3). 
The combined organic fractions were washed with water (3 x 100 cm3), dried 
(MgSC>4), filtered and concentrated under reduced pressure to give a colourless oil 
which solidified on drying under high vacuum to give the title compound (34) as a 
white solid (21.14g, 96%). 8h (CDC13) 1.44 (9H, s, OC(CH3)3), 2.05 (1H, br s, OH),
~ 3.95 (2H, ddd, J=7.15, 7.15 Hz, CH2OH), 4.40 (1H, br s, NCHC02),
5.20 (2H, s, CH2Ph), 5.51 (1H, br s, NH), 7.35 (5H, s, aromatics) ppm. 8c (CDC13)
28.5 (C(CH3)3), 56.0 (CHC02), 60.6 (CH2OH), 67.6 (CH2Ph), 80.5 (C(CH3)3), 128.3,
128.6, 128.8 (C-aromatics), 135.4 ((Ar)C-CH2C02), 156.5 (NHC02),
170.9 (C02CH2Ph) ppm. mp 70-71 °C (Lit.42 70-71 °C). m/z (FAB) 296 (M+l)+ (8%), 
240 (M+l - H2C=C(CH3)2)+ (15%), 196 (49%).
(S)-Benzyl-2-[(tert-butoxycarbonyl)amino]-3-p-toluenesulphonylpropionate (35) - 
Tosyl chloride (7.1g, 37.16 mmol) was added to a stirred solution of (34)
(lOg, 33.78 mmol) in dry pyridine (50 cm3) under nitrogen at -10°C. The resulting 
solution was stirred for 24 hours at <0°C. The solution was then poured into ice/water 
(1:1, 200 cm3) and stirred until a white solid crystallised out of solution.
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The solid was filtered off and washed with water (3 x 50 cm3) and the washed with a 
small amount of cold ethanol, then dried under high vacuum. The crude product was 
recrystallised from ethanol to give the title compound (35) as a white solid (10.44g, 
68.5%). 8h (CDC13) 1.40 (9H, s, OC(CH3)3), 2.43 (3H, s, pSC bC ^O L ), (2H, ddd, 
J=2.93, 19.42 Hz, CH20 S 0 2), 4.53 (1H, bd, J=8.24 Hz, NCHC02), 5.12 (2H, dd,
J= 12.27,13.01 Hz, CH2Ph), 5.35 (1H, bd, J=8.25 Hz, NH), 7.30 (7H, m, OfcGsHs 
and tosyl meta protons), 7.71 (2H, d, J=8.24 Hz, tosyl ortho protons) ppm. 6c (CDC13)
21.6 (S02C6H4CH3), 28.2, (C(CH3)3), 53.0 (NCHC02), 67.8 (CH2Ph), 69.5 
(CH2OS02), 80.4 (C(CH3)3), 127.9,128.2,128.5,128.6,129.9 (C-aromatics), 132.3 
((Ar)-C-CH3), 134.7 ((Ar)-C-CH2C02), 145.1 ((Ar)-C-S02), 154.9 (NHC02), 168.4 
(C02CH2Ph) ppm. m/z (FAB) 450 (M+l)+ (20%), 394 (M+l - H2C=C(CH3)2)+ 
(100%), 350 (30%).. mp 95-97 °C (L it.42 95-96 °C).
(R)-Benzyl‘2-[(tert-butoxycarbonyl)amino]-3-iodopropionate (36) - A solution of 
sodium iodide (2.0g, 13.3 mmol) in dry acetone (20 cm3) was added dropwise to a 
stirred solution of (35) (4.0g, 8.9 mmol) in dry acetone (20 cm3) under nitrogen in the 
_ absence o f light. The resulting yellow solution was stirred at room temperature, in the 
dark, for 24 hours. The reaction mixture was then filtered and concentrated under 
reduced pressure. The residue was then dissolved in chloroform (100 cm3), washed 
sequentially with water (2 x 50 cm3), sodium thiosulphate (50 cm3), and again with 
water (3 x 50 cm3), then dried (MgS0 4 ), filtered and concentrated under reduced 
pressure to give a pale yellow oil. The oil was dried under high vacuum then dissolved 
in a minimum of hot ethanol and stored in the freezer overnight. A white solid 
crystallised out of solution and was filtered off and washed with a small amount 
amount of cold ethanol After drying under high vacuum the title compound (36) was 
isolated as a white solid (1.96g, 54%). The product requires storage in the dark under 
a nitrogen atmosphere at ambient temperature, mp 79-80 °C (Lit.42 79-80 °C). 8h 
(CDC13) 1.45 (9H, s, C(CH3)3), (2H, m, CH2I), 4.58 (1H, m, NCHC02), 5.20 (2H, dd, 
J=3.3, 12.2 Hz, CH2Ph), 5.40 (1H, bd, J= 7.5 Hz, NH), 7.37 (5H, s, aromatics) ppm.
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8 c (CDCI3) 8.0 (CH2I), 28.4 (C(CH3)3), 53.8 (NCHC02), 68.2 (CH2Ph),
80.7 (C(CH3)3), 128.4, 128.7, 128.8 (CH-aromatics), 135.0 (C-aromatics)„ 152.9 
(NC02), 169.7 (C02CH2Ph) ppm. m/z (FAB) 406 (M+l)+ (5%), 350
(M+l - H2C=C(CH3)2)+ (60%), 306 (40%).
(d) - 3- Butyn-2-oxy-p-toluensulphonte (41) - Tosyl chloride (15.0g, 78.6 mmol) was 
added to a stirred solution of (±)-3-butyn-2-ol (5.0g, 71.4 mmol) in dry pyridine 
(50 cm3) under nitrogen at -10°C. The solution was for 2 hours at -10°C and then 
stored in the freezer for 24 hours. The solution was then poured in ice / water 
(1:1,200 cm3) and stirred for 20 minutes. The aqueous was then extracted with ethyl 
acetate (3 x 100 cm3) and the combined organic fractions washed with 2M HC1 
(3 x 50 cm3), NaHC03 (50 cm3), and water (50 cm3). The organic portions were then 
dried (MgSC>4), filtered and concentrated under reduced pressure to give an orange oil 
which solidified on storage in a freezer. The crude solid product was crystallised from 
ethanol to give the title compound (41) as a white solid (15.06g, 88%).
5h  (CDC13) 1.58 (3H, d, CHjCH), 2.43 (1H, d, O C H ), 2.50 (3H, s, Ar-CH3),
5.16 (1H, dq, CH-OCH), 7.33 (2H, d, tosyl meta protons), 7.82 (2H, d, tosyl ortho 
protons) ppm. 8C (CDC13) 21.8 (Ar-CH3), 22.7 (CH3CH), 67.5 (CH-C^CH),
75.7 (CH-OCH), 80.0 (CH-OCH), 128.2, 129.9 (CH-aromatics), 133.9 ((Ar)CCH3) 
145.1 ((Ar)CS02) ppm. m/z (C.I.) 224 (M +l)+ (4%), 167 (100%), 41 (20%).
Benzyl 2-(S)-[(tert-butoxycarbonyl)amino]-hepta-4,5-dienoate (42) - A suspension of 
zinc powder (1.3g, 20.1 mmol) in dry THF (10 cm3) and 1,2-dibromoethane (0.4g, 0.2 
cm3, 4.7 mmol) was heated under nitrogen to 60°C and stirred at this temperature for 5 
minutes. After cooling to 35°C, trimethylsilylchloride (0.03 cm3, 0.2 mmol) was added 
and the reaction mixture stirred vigorously for 30 minutes at 35°C. A solution of (36)
( 1.81g, 4.46 mmol) in dry THF (5 cm3) was added dropwise and the reaction stirred 
for 45 minutes.
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The solution was then cooled to 0°C and a solution of (41) (l.Og, 4.46 mmol) and 
tetrakis(triphenylphosphine) palladium (0) (0.30g, 0.268mmol) in dry THF (5 cm3) was 
added. The reaction was stirred at -10°C for 16 hours. The reaction mixture was then 
treated with ethyl acetate (30 cm3) and filtered through celite. The organic portion was 
then washed with 0.1 M HC1 (50 cm3) and distilled water (3 x 75 cm3). The organic 
portion was then dried (Na2SC>4), filtered and concentrated under reduced pressure to 
give a brown oil, the analytical data on which did not correspond to the desired 
product (42).
Benzyl 2-(S)-[(tert-butoxycarbonyl)amino]-hepta-4,5-dienoate (42) - A suspension of 
zinc powder (1.3g, 20.1 mmol) in dry THF (10 cm3) and 1,2-dibromoethane (0.4g, 0.2 
cm3, 4.7 mmol) was heated under nitrogen to 60°C and stirred at this temperature for 5 
minutes. After cooling to 35°C, trimethylsilylchloride (0.03 cm3, 0.2 mmol) was added 
and the reaction mixture stirred vigorously for 30 minutes at 35°C. A solution of (36) 
(1.81g, 4.46 mmol) in dry THF (5 cm3) was added dropwise and the reaction stirred 
for 45 minutes. The solution was then cooled to -10°C and a solution of copper (I) 
cyanide (0.30g, 3.4 mmol) and lithium chloride (0.30g, mmol) in dry THF (2 cm3) was 
added. The reaction was stirred at 0°C for 10 minutes then cooled to -10°C before the 
addition o f a solution of (41) (l.Og, 4.46 mmol) in dry THF (2 cm3). The reaction was 
stirred at -10°C for 16 hours. The reaction mixture was then treated with ethyl acetate 
(30 cm3) and filtered through celite. The organic portion was then washed with 0.1 M 
HC1 (50 cm3) and distilled water (3 x 75 cm3). The organic portion was then dried 
(Na2SC>4), filtered and concentrated under reduced pressure to give the title compound 
(42) as a yellow oil (1.27g, 8 6 %). 8 h (CDC13) 1.45 (9H, s, C(CH3)3), 1.67 (3H, dd,
J= 7, 3.5 Hz, CHaCH) 2.45 (2H, m, CH2CH), 4.45 (1H, m, CH2CH), 4.90 (1H, m, 
CH3CH=C=C), 5.05-5.25 (3H, m, CH2CH=C=C and CHzPh), 7.38 (5H, s, aromatics) 
ppm. 5c (CDC13) 14.4 (CH3CH=C=C), 28.5 (C(CH3)3), 32.2 (CH2CH=C=C),
53.3 (NCHCO2), 67.2 (CH2Ph), 80.0 (C(CH3)3), 8 4 . 6  (C=C=CHCH2),
8 6 . 6  (C=C=CHCH3), 128.2, 128.4,128.6 (CH-aromatics), 135.6 ((Ar)-CCH2),
156.0 (NHCO2), 172.1 (C02CH2Ph), 207.2 (C=C=C) ppm. m/z (FAB) 332 (M +l)+ 
(20%), 276 (M+l - C4H8)+ (100%), 232 (60%).
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(±)-AllyI glycine benzylester benzenesulphonate (45) - A mixture of (±)-allylglycine 
(lO.Og, 87 mmol), technical grade benzenesulphonic acid (17.2g, 108.7 mmol) and 
benzyl alcohol (50 cm3) in carbon tetrachloride (200 cm3) was refluxed using a 
modified Dean-Stark apparatus until no more water was collected (16 hours). The 
reaction mixture was then concentrated under reduced pressure and the resulting oil 
treated with diethyl ether (200 cm3) and stirred vigorously. The solution was then 
stored at <0°C for 24 hours and a white solid crystallised and was filtered off. The 
solid was washed with fresh, cold diethyl ether and dried under high vacuum to give 
the title compound (45) as a white solid (12.4g, 40%).
8h (CDC13) 2.55 (2H, m, CH2CHCCH 2), 4.25 (1H, m, NHCHC02), 5.00 (4H, m, 
CH2=CH and CHzPh), 5.55 (1H, m, CH2=CH), 7.2-7.4 (8H, m, CH2C6H5 and PhS03* 
meta and para protons), 7.88 (2H, d, J=7.5 Hz, PhS03* ortho protons), 8.1-8.4 (1H, 
bs, NH) ppm. 6c (CDC13) 34.5 (CH2CH=CH2), 52.9 (NCHC02), 68.0 (CH2Ph),
121.3 (CH2CH=CH2), 128.2, 128.6,128.7, 129.9 (CH-aromatics), 130.4 
(CH2CH=CH2), 134.9 ((Ar)CCH2), 144.4 ((Ar)CS03), 168.9 (C02CH2Ph) ppm.
(i) -N-t-Butoxycarbonylallylglycine benzylester (46) - Di-tert-butylpyrocarbonate 
(7.25g, 33.2 mmol) was added to an ice cooled solution of (45) (12.0g, 33.2 mmol) in 
dry THF (80 cm3) and aqueous 1M sodium hydroxide (35 cm3). The resulting solution 
was stirred at room temperature for 16 hours and then concentrated under reduced 
pressure, cooled in an ice bath, treated with ethyl acetate (100 cm3) and adjusted to pH 
3 with 10% aqueous potassium hydrogen sulphate. The two layers were separated and 
the aqueous phase was washed with fresh ethyl acetate (2 x 100 cm3). The combined 
organic layers were washed with water (3 x 50 cm3), dried (Na2SC>4), filtered and 
concentrated under reduced pressure to give the title compound (46) as a colourless oil 
(9.43g, 93%). 8h (CDC13) 1.42 (9H, s, (C(CH3)3), 2.55 (2H, m, CH2CH=CH2), 4.45 
(1H, m, NHCHCO2), 5.20 (4H, m, CH2=CH and CHzPh), 5.65 (1H, m, CH2=CH),
7.35 (5H, s, CHzCgHs) ppm. 8C (CDC13) 28.5 (C(CH3)3), 36.9 (CH2CH=CH2), 53.1 
(NCHCOz), 67.2 (CH2Ph), 80.1 (C(CH3)3), 119.4 (CH2CH=CH2), 128.5,128.6,
128.7, (CH-aromatics), 132.4 (CH2CH=CH2), 135.5 ((Ar)CCH2), 155.4 (NHC02),
172.1 (C02CH2Ph) ppm. m/z (FAB) 306 (M+l)+ (8%), 250 (100%), 206 (28%).
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(±)-N-t-Butoxycarbonylaspartic acid-ft-semialdehyde benzylester (43) - A solution of 
(46) (5.0g, 16.3 mmol) in dry DCM (300 cm3) was flushed with ozone for two hours 
and the reaction followed by tic (20% EtOAc/petrol). When all the starting material 
had reacted the flask was flushed with nitrogen to remove any excess ozone. The 
ozonide was decomposed by treating the solution with triethylamine (3.3g,
32.7 mmol) at -78°C over 20 minutes, and stirring the resulting solution for a further 5 
hours at room temperature. The solution was concentrated under reduced pressure, 
then treated with ethyl acetate (100 cm3) to precipitate triethylamine-N-oxide. The 
suspension was filtered and the filtrate washed with water (3 x 100 cm3), dried . 
(Na2SC>4), filtered and concentrated under reduced pressure to give the crude aldehyde 
as an oil. The crude product was purified by column chromatography [silica gel, 
petrol-EtOAc (4:1)] to yield the title compound (43) as a colourless oil (3.64g, 73%). 
6h (CDCIs) 1.45 (9H, s, (C(CH3)3), 3.05 (2H, m, CHzCHO), 4.65 (1H, m,
NHCHCOz), 5.15 (4H, s, CHzPh), 5.40 (1H, bd, J=8.0 Hz, NH), 7.35 (5H, m, 
CH2C6H5), 9.70 (1H, s, CHO) ppm. 6c (CDC13) 28.4 (C(CH3)3), 46.1 (CH2CHO),
48.9 (NCHCO2), 67.8 (CH2Ph), 77.7 (C(CH3)3), 128.6,128.7, 128.8, (CH-aromatics),
135.3 ((Ar)CCH2), 155.7 (NHC02), 171.1 (C02CH2Ph), 199.6 (CHO) ppm. m/z 
(FAB) 308 (M +l)+ (10%), 252 (80%), 206 (55%).
(d)-Allylglycine-t-butyl ester hydrochloride (47) - 2-Methylpropene gas (400 cm3) was 
bubbled through a stirred solution of (±)-allylglycine (5.0g, 43.48 mmol) in DCM 
(300 cm3) at -78°C. Once all the gas had been added to the reaction mixture 
concentrated sulphuric acid (5 cm3) was added dropwise over 20 minutes, and the 
solution stirred at -78°C for 30 minutes. The solution was allowed to warm to room 
temperature overnight then adjusted to pH 8 with saturated aqueous sodium 
bicarbonate solution. The two layers were separated and the organic layer washed with 
saturated brine solution (2 x 50 cm3), dried (MgSC>4), filtered and concentrated under 
reduced pressure. The resulting oil was taken up in diethyl ether and stirred vigorously 
while concentrated hydrochloric acid was added dropwise until pH 2.
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The solution was stored in a freezer overnight and a white solid crystallised out o f 
solution which was filtered off, washed with fresh diethyl ether and dried under high 
vacuum to give the title compound (47) as a white solid (7.54g, 84%). 8h (CDCI3) 
1.49 (9H, s, C(CH3)3), 2.81 (2H, m, CH2C H C H 2), 4.06 (1H, m, NCHC02), 5.28 
(2H, m, CH2=CHCH2), 5.83 (1H, m, CH2=CHCH2), 8.73 (3H, bs, NH3) ppm.
6c (CDC13) 27.9 (C(CH3)3), 34.0 (CH2=CHCH2), 52.9 (NCHC02), 84.0 (C(CH3)3),
121.1 (CH2=CHCH2), 130.1 (CH2=CHCH2), 167.3 (NCHC02)ppm
(dj-N-t-Butoxycarbonylallylglycine-t-butyl ester (48) - Di-tert-butylpyrocarbonate 
(7.9 lg, 36.2 mmol) was added to an ice cooled solution of (47) (7.5g, 36.2 mmol) in 
dry THF (100 cm3) and aqueous 1M sodium hydroxide (35 cm3). The resulting 
solution was stirred at room temperature for 16 hours and then concentrated under 
reduced pressure, cooled in an ice bath, treated with ethyl acetate (100 cm3) and 
adjusted to pH 3 with 10% aqueous potassium hydrogen sulphate. The two layers 
were separated and the aqueous phase was washed with fresh ethyl acetate 
(2 x 100 cm3). The combined organic layers were washed with water (3 x 50 cm3), 
dried (Na2SC>4), filtered and concentrated under reduced pressure to give the title 
compound (48) as a colourless oil (8.2g, 95%). 8h (CDC13) 1.45 (9H, s, 
NHC02C(CH3)3), 1.46 (9H, s, CHC02C(CH3)3), 2.49 (2H, m, CH^CHCIL),
4.25 (1H, m, NCHC02), 5.13 (3H, m, CH2=CHCH2 and NH), 5.72 (1H, m, 
CH2=CHCH2) ppm 8c (CDC13) 27.9 (CHC02C(CH3)3), 28.2 (NHC02C(CH3)3),
36.9 (CH2=CHCH2), 53.2 (NCHC02), 79.6 (CHC02C(CH3)3),
81.8 (NHC02C(CH3)3), 118.6 (CH2=CHCH2), 132.4 (CH2=CHCH2), 155.2 (NHC02),
170.8 (CHC02) ppm m/z (FAB) 272 (M +l)+ (15%), 216 (100%), 172 (65%).
( -N-t-Butoxycarbonylaspartic acid-/?-semialdehyde-t-butyl ester (49) - A solution 
of (48) (4.2g, 17.6 mmol) in dry DCM (300 cm3) was flushed with ozone for five 
hours and the reaction followed by tic (20% EtOAc/petrol). When all the starting 
material had reacted the flask was flushed with nitrogen to remove any excess ozone.
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The ozonide was decomposed by treating the solution with triethylamine (3.8g, 35.14 
mmol) at -78°C over 20 minutes, and stirring the resulting solution at room 
temperature overnight. The solution was concentrated under reduced pressure, then 
treated with ethyl acetate (200 cm3) to precipitate triethylamine-N-oxide. The 
suspension was filtered and the filtrate washed with water (3 x 100 cm3), dried 
(Na2SC>4), filtered and concentrated under reduced pressure to give the crude aldehyde 
as an oil. The crude product was purified by column chromatography [silica gel, 
petrol-EtOAc (4:1)] to yield the title compound (49) as a colourless oil (1.8g, 43%). 
8h (CDC13) 1.44 (9H, s, NHC02C(CH3)3), 1.45 (9H, s, CHCOzQCH^),
2.99 (2H, dq, CH2CHO), 4.48 (1H, m, NCHC02), 5.40 (1H, m, J=7.69, NH),
9.74 (1H, s, CHO) ppm. 8C (CDC13) 27.6 (CHC02C(CH3)3), 27.7 (NHC02C(CH3)3),
46.3 (NCHC02), 49.2 (CH2CHO), 79.9 (CHC02C(CH3)3), 82.6 (NHC02C(CH3)3),
155.3 (NHCOz), 171.0 (CHC02), 199.3 (CHO) ppm. m/z (FAB) 274 (M+l)+ (5%), 
218 (75%), 174 (60%).
Tert-butyl 2-(N-tertbutoxycarbonylamino)-4-hydroxy-6-(trimethylsilyl)hex-5-ynoate - 
A solution of (49) (500mg, 2.1 mmol) in dry THF (10 cm3), under a nitrogen 
atmosphere, was cooled to -20°C then treated dropwise with a 0.5M solution of 
lithium (trimethylsilyl)acetylide in THF (4.2 cm3, 2.1 mmol). After 2 hours the reaction 
was allowed to warm to room temperature and treated with a solution of saturated 
aqueous ammonium chloride (25 cm3). The solution was then extracted with 
dichloromethane (3 x 50 cm3). The combined organic extracts were dried (MgS0 4 ), 
filtered and concentrated under reduced pressure to give an orange oil (546mg), the 
analytical data on which did not correspond to the desired product.
Dimethyldioxirane (53) - To a solution of NaHC03 (47g, 0.559 mol) in water 
(200 cm3) and acetone (150 cm3) was added potassium monoperoxysulphate 
(lOOg, 0.833 mol) in 20g portions at -78°C with vigorous stirring.
I l l
5 minutes after the last addition of potassium monoperoxysulphate the reaction was 
allowed to warm to room temperature and a moderate vacuum (80-100 torr) was 
applied to distil off the DMDO / acetone 5% solution, which was collected in a 
receiving flask cooled to -78°C. The product was dried (K2CO3) and stored in the 
freezer (-20°C) over molecular sieves (4A).
Tert-butyl 2-(N-tertbutyloxycarbonyl amino)pent-4-enoate epoxide (54a) - To a 
solution of (48) (0.22g, 0.82 mmol) in acetone (10 cm3), cooled to -5cC, was added a 
solution of (53) (10 cm3). The solution was stirred for 1 hour and then concentrated 
under reduced pressure. The crude product was dissolved in EtOAc (10 cm3), dried 
(MgSC>4), filtered and concentrated under reduced pressure to give the title compound 
(54a) as a reddish oil (0.2g, 84%).6h  (CDC13) 1.45 (9H, s, NHC0 2C(CH3)3), 1.48 (9H, 
s, CHC0 2C(CH3)3), 1.94 (2H, t, J=6 Hz, CH2CHN),2 .49  (1H, m, C&HbOCH), 2.78 
(1H, t, J=5 Hz, CHaHbOCH), 3.03 (1H, m, CHaHbOCH), 4.34 (1H, m, N CHC02),
5.35 (1H, m, J=7.8, NH), ppm. 6c (CDC13) 27.8 (CHC02C(CH3)3), 28.2 
NHC02C(CH3)3), 35.6 (CILOCH), 35.8 (OkCHN), 46.7 (NCHC02), 52.3 
(CH2OCH), 79.7 (CHC02C(CH3)3), 82.2 (NHC02C(CH3)3), 155.2 (NHC02), 170.9 
(CHC02) ppm. m/z 288 (M +l)+ (15%), 272 (55%), 232 (100%), 188 (40%).
Tert-butyl 2-(N-tertbutyloxycarbonyl amino)pent-4-enoate epoxide (54b) - 
m-Chloroperbenzoic acid (0.26g, 1.48 mmol) was added to an ice cooled solution of 
(48) (0.20g, 0.74 mmol) in dry DCM (10 cm3) under nitrogen atmosphere. The 
reaction mixture was stirred at 0-5°C for 14 hours then treated with an aqueous 
solution of 1M NaHCC>3 (20 cm3), and the solution stirred for 20 minutes.
The two layers were separated and the aqueous washed with fresh DCM (2 x 50 cm3). 
The combined DCM washes were washed with distilled water (3 x 50 cm3), dried 
(Na2SC>4), filtered, and concentrated under reduced pressure. The crude product was 
purified by column chromatography [silica gel, petrol-EtOAc (4:1)] to yield the title 
compound (54b) as a colourless oil (0.116g, 55%).8h  (CDCI3)
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1.45 (9H, s, NHC02C(CH3)3), 1.46 (9H, s, CHC02C(CH3)3), 2.01 (2H, t, J=6 Hz, 
CH2CHN),2.45 (1H, m, CHaHbOCH), 2.75 (1H, t, J=5 Hz, CHaHbOCH),
2.97 (1H, m, CHaHbOCH), 4.30 (1H, m, N CHC02), 5.38 (1H, m, J=7.8, NH), ppm.
6c (CDC13) 27.7 (CHC02C(CH3)3), 28.2 (NHC02C(CH3)3), 35.7 (CHzOCH),
35.9 (CHzCHN), 46.6 (NCHC02), 52.2 (CH2OCH), 79.8 (CHC02C(CH3)3),
82.3 (NHC02C(CH3)3), 155.3 (NHC02), 171.0 (CHC02) ppm. m/z 288 (M+l)+ 
(15%), 272 (55%), 232 (100%), 188 (40%).
Tert-butyl 2-(N-tertbutoxycarbonylamino)-4-hydroxy-6-(trimethylsilyl)hex-5-ynoate - 
Cerium chloride heptahydrate (0.4 lOg, 1.1 mmol) was finely ground and placed in a 
two necked round bottom flask, which was placed in an oil bath and heated in vacuo 
to 135-140°C at 0.5 mmHg for 2 hours. Nitrogen was then added to the flask which 
was then cooled in an ice bath and dry THF (5 cm3) added. After stirring in an 
ultrasonic bath at room temperature for 1 hour the resulting slurry was cooled to -78°C 
and treated dropwise with a 0.5M solution of lithium (trimethylsOyl)acetylide in THF 
(1.5 cm3, 0.75 mmol), and the solution stirred for 1 hour. A solution of (49) (0.20g,
0.75 mmol) in THF (3 cm3) was added dropwise and the solution stirred at -78°C for 
18 hours. The reaction mixture was then treated with a saturated aqueous solution of 
ammonium chloride (20 cm3), followed by ethyl acetate (40 cm3). The solution was 
stirred for 10 minutes, the two layers were then separated, and the aqueous extracted 
with fresh EtOAc (3 x 40 cm3). The combined organic layers were dried (Na2C03), 
filtered and concentrated under reduced pressure to give a brown oil, the analytical 
data on which did not correspond to the desired product.
Tert-butyl 2-(N-tertbutoxycarbonylamino)-4-hydroxy-6-phenylhex-5-ynoate (57) - 
Cerium chloride heptahydrate (0.20g, 0.55 mmol) was finely ground and placed in a 
two necked round bottom flask, which was placed in an oil bath and heated in vacuo 
to 135-140°C at 0.5 mmHg for 2 hours. Nitrogen was then added to the flask which 
was then cooled in an ice bath and dry THF (2 cm3) added.
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After stirring in an ultrasonic bath at room temperature for 1 hour the resulting slurry 
was cooled to -78°C and treated dropwise with a 1M solution of lithium 
phenylacetylide (0.55 cm3, 0.55 mmol), and the solution stirred for 1 hour. A solution 
of (49) (0.1 Og, 0.37 mmol) in THF (2 cm3) was added dropwise and the solution 
stirred at -78°C for 18 hours. The reaction mixture was then treated with a saturated 
aqueous solution of ammonium chloride ( 1 0  cm3), followed by ethyl acetate ( 2 0  cm3). 
The solution was stirred for 10 minutes, the two layers were then separated, and the 
aqueous extracted with fresh EtOAc (3 x 20 cm3). The combined organic layers were 
dried (Na2CC>3), filtered and concentrated under reduced pressure. This gave a brown 
oil which was purified by column chromatography [silica gel, petrol-EtOAc (3:1)] to 
yield the title compound (57) as a yellow oil (0.08g, 60%). 8 h (CDCI3) 1.46 (9H, s, 
NHC0 2C(CH3)3), 1.48 (9H, s, CHC0 2C(CH3)3), 1.7-2.4 (2 H, m, Cf^CHN), 3.68 
(1H, m CH2CHOH), 4.46 (1H, m, NCHC02), 5.46 (1H, m, J=7.6, NH), 7.28-7.44 
(5H, m, aromatics) ppm. 6 C (CDC13) 27.9 (CHC02C(CH3)3), 28.2 (NHC02C(CH3)3),
40.3 (CH2CHOH), 59.6 (CH2CHOH), 80.3 (CHC02C(CH3)3), 80.7 (OCCHOH),
82.6 (NHC02C(CH3)3), 88.9 (PhC^C), 122.6 (aromatics(C)-C=C), 128.2, 131.7,
131.8 (aromatics(CH), 155.8 (NHC02), 169.9 (CHC02) ppm.
Tert-butyl 2-(N-tertbutoxycarbonylamino)-4-hydroxy-4-thiophen-2-ylbutanoate (61)- 
A 0.25M solution of lithium-2-thienylcyanocuprate in THF (8.25 cm3, 2.06 mmol), at 
-78°C under a nitrogen atmosphere, was treated dropwise with an 11% suspension of 
sodium acetylide in xylene (0.085g, 1.9 ml, 2.06 mmol) and the solution stirred at 
-78°C for 1 hour. A solution of (49) (0.500g, 2.06 mmol) in THF (2 ml) was added in 
one portion and the reaction allowed to warm to room temperature over 2 hours. The 
THF was removed under reduced pressure and the resulting oil taken up in EtOAc (20 
cm3), then treated with a saturated aqueous solution of ammonium chloride (15 cm3) 
and stirred for 10 minutes at room temperature. The two layers were separated, and 
the aqueous wahed with fresh EtOAc (3 x 20 cm3). The combined EtOAc layers were 
washed with distilled water ( 2  x 50 cm3), dried (Na2S0 4 ), filtered and concentrated 
under reduced pressure to give a brown oil.
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This was purified by column chromatography [silica gel, petrol-EtOAc (2:1)] to yield 
the title compound (61) as an oil (0.40g, 61%). 6 h (CDCI3) 1.44 (9H, s, 
NHC0 2C(CH3)3), 1.45 (9H, s, C0 2C(CH3)3), 2.71-2.97 (2 H, dq, J=4.8, 1 2 . 1  Hz, 
CHOHCIL), 4.30 (1H, t, J=6.7 Hz, CHOH), 4.45 (1H, m, NCHC02), 5.45 (1H, bd, 
J=8.25 Hz, NH), 6.99-7.74 (3H, m, Thienyl CH) ppm. 6 C (CDCI3) 27.8 (C02C(CH3)3),
28.3 (NHC02C(CH3)3), 50.4 (NCHC02), 60.8 (CHOHCH2), 65.5 (CHOHCH2),
79.8 (C02C(CH3)3), 82.2 (NHC02C(CH3)3), 123.7, 124.3, 127.0 (Thienyl-CH),
130.9 (Thienyl-C), 155.4 (NHC02C(CH3)3), 170.0 (C02C(CH3)3) ppm.
Tert-butyl 2-(N-tertbutoxycarbonylamino)-4-hydroxy-pentanoate (6 6 ) - Copper (II) 
cyanide (0.74g, 0.82 mmol) in THF (1 cm3) was treated dropwise with a 1.0M solution 
of methyllithium in THF (2equiv, 1.65 cm3, 1.65 mmol) at -78°C, under nitrogen, and 
the solution stirred for 30 minutes. The reaction mixture was allowed to warm to room 
temperature and treated dropwise with tributyl(ethynyl)tin (0.24 cm3, 0.82 mmol) and 
the solution stirred at room temperature for 1 hour. The solution was cooled again to - 
78°C and treated dropwise with a solution of (49) (0.200g, 0.823 mmol) in THF (2 
cm3) and the solution allowed to warm to room temperature overnight. The THF was 
removed under reduced pressure, then saturated aqueous solution of ammonium 
chloride (10 cm3) and EtOAc (20 cm3) were added, and the solution stirred for 10 
minutes. The two layers were separated and the aqueous washed with fresh EtOAc (3 
x 30 cm3). The combined EtOAc layers were washed with distilled water (2 x 100 
cm3), dried (Na2S0 4 ), filtered and concentrated under reduced pressure to give a 
yellow oil. The crude product was purified by column chromatography [silica gel, 
petrol-EtOAc (3:1)] to yield the title compound (6 6 ) as a colourless oil (0.190g, 
89%).6h  (CDCI3) 1.45 (9H, s, NHC0 2C(CH3)3), 1.46 (9H, s, C0 2C(CH3)3), 1.64 (3H, 
m, CH3CHOH), 2.75-3.05 (2H, dq, J=5.1, 12.4 Hz, CHOHCHz), 4.15 (1H, m,
CHOH), 4.48 (1H, m, NCHC02), 5.45 (1H, bd, J=8.7 Hz, NH), ppm. 8 C (CDC13) 26.8 
(CH3CHOH), 27.8 (C02C(CH3)3), 27.9 (NHC02C(CH3)3), 50.5 (NCHC0 2), 60.8 
(CHOHCH2), (NHC02C(CH3)3), 155.0 (NHC02C(CH3)3), 170.0 (C02C(CH3)3) ppm.
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Benzyl 2-(N-tertbutyloxycarbonylammo)-3-triethoxyphononylpropionate (69) - 
A solution of (36) (l.Og, 2.46 mmol) and triethylphosphite (0.4lg, 2.46 mmol) in dry 
THF (20 cm3) was stirred at reflux for 16 hours. The reaction mixture was then 
concentrated under reduced pressure and the resulting oil purified by column 
chromatography [silica gel, MeOH-DCM (1:20)] to yield the title compound (69) as a 
white solid (0.65g, 65%). 8h (CDC13) 1.35 (6H, t, J=7.02 Hz, 2 x POCH2CH3),
1.44 (9H, s, C(CH3)3), 3.55 (2H, m, CH2P), 4.09 (4H, dq, J=7.02 Hz, 2 x 
POCH2CHO, 4.55 (1H, m, NCHCO2), 5.21 (2H, s, CH2Ph), 5.43 (1H, bd, J= 7.63 
Hz, NH), 7.37 (5H, s, aromatics) ppm. 6c (CDC13) 7.6 (CH2P), 15.8 (POCH2CH3),
16.2 (POCH2CH3), 28.1 (C(CH3)3), 53.2 (NCHC02), 67.7 (CH2Ph), 80.3 (C(CH3)3),
128.4,128.6,129.7 (CH-aromatics), 134.7 (C-aromatics), 154.7 (NC02),
169.8 (C02CH2Ph) ppm. m/z (FAB) 416 (M+l)+ (6%), 325 (M+l - CH2Ph)+ (20%), 
279 (M+l - PO(OEt)2)+ (25%), 280 (M+l - C02CH2Ph)+ (100%), 91 (100%).
Propynal (70) - A solution of chromium trioxide (30.0g, 0.3 mol) in concentrated 
sulphuric acid (20 cm3) and water (60 cm3) was added dropwise over 1 hour to a 
solution of propynol (18.0g, 18.7 cm3, 0.3 mol) in MEK (50 cm3). The temperature 
was maintained between 20-25°C using an ice/water bath. After addition was complete 
the reaction mixture was stirred for 4 hours and then diluted with water (50 cm3). The 
organic layer was separated and the aqueous washed with diethyl ether (2 x 50 cm3). 
The combined organic extracts were dried (Na2SC>4), filtered, and concentrated under 
reduced pressure. The residual liquid was distilled at atmospheric pressure 
(b.p. 54-57°C) to give three batches of the title compound (70) all contaminated with 
MEK, (total yield=15.6g, 90%). 6h (CDC13) 3.71 (1H, s, H O C), 9.22 (1H, s, CHO) 
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